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ABSTRACT 
Down syndrome (DS) (OMIM #190685), the most common viable chromosome 
abnormality, is associated with an increased risk of medical complications.  The most 
frequent endocrine abnormalities observed in children with DS involve the thyroid gland, 
and the risk of thyroid dysfunction increases with age.  Global studies have documented a 
wide spectrum of thyroid dysfunction in children with DS. 
 
Due to the paucity of data from sub-Saharan Africa regarding thyroid function in African 
children with DS, this study was conceived.   The main aim of the study was to document 
the range of thyroid function in a cohort of 391 South African children with DS, seen at the 
Genetic Clinics from 2003 to 2008.  Referral and treatment practices at two tertiary 
hospitals in Johannesburg were also documented.  The majority (84%) of children had at 
least one thyroid function test (TFT) performed, and the most common form of thyroid 
dysfunction encountered was subclinical hypothyroidism (25.3%).  Notably, up to one 
third of patients with abnormal TFT results were not referred to the Endocrine Clinics for 
evaluation, and were thus not receiving the necessary treatment.  There were 13 neonates 
with congenital hypothyroidism; at least two of them were not referred, and thus not 
treated during the sensitive neonatal period.   
 
A significant difference was noted between the results from Chris Hani Baragwanath 
Hospital and those from the other two hospitals.  The difficulties in interpretation of results 
obtained from different biochemical machines and different populations, as compared to 
those used to derive the reference ranges, were raised.  Problems with regular follow-up of 
patients and annual thyroid surveillance were also highlighted.   
 
V 
 
The clinical features of hypothyroidism may be difficult to distinguish from the phenotypic 
features of DS.  Thus, regular biochemical screening, even in the absence of physical signs 
and symptoms, is warranted in this group of children to ensure that hypothyroidism is 
treated, and further, irreversible neurological and physical impairment prevented.   
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1. INTRODUCTION 
1.1 DOWN SYNDROME 
 
Down syndrome (DS) (OMIM #190685) is the most common chromosomal abnormality 
observed in live-born infants, and the most frequent genetic cause of mental retardation. 
DS is a congenital disorder caused by the presence of a third copy of the whole or a critical 
part of chromosome 21 (Trisomy 21).  In most affected individuals (94%), the trisomy of 
chromosome 21 involves the whole chromosome through maternal or paternal non-
disjunction, whereas in others (3.3%) DS is the result of an unbalanced translocation or of 
mosaicism of trisomy 21 (2.4%)  (Thuline and Pueschel, 1982) . 
 
DS is named after Dr John Langdon Down, who identified and described the typical 
phenotypic features in 1866.  Live-birth rates for DS from around the globe range between 
1.5 per 1000 (1 in 660 infants) (Penrose and Smith, 1966) and 1.2 per 1000 (1 in 826 
infants) (Hook, 1992), with no predilection for race or socio-economic group.  Studies 
conducted in South Africa show a DS prevalence of 1.8 and 2.09 per 1000 live births in 
hospital-based studies in urban and rural populations, respectively (Venter, Christianson, 
Gericke et al., 1995; Christianson, 1996). 
 
The birth prevalence of DS increases with advancing maternal age (Hook, 1992).  In some 
populations the overall birth prevalence of DS has decreased due to increased use of 
contraception, prenatal screening programmes and the availability of termination of 
pregnancy.  These programmes offer prenatal invasive testing to women of advanced 
maternal age, and others who are at high risk of carrying a fetus with a chromosomal 
abnormality (Carothers, Boyd, Lowther et al, 1999; Benn, Egan, Fang et al, 2004).  There 
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is a paucity of data from South Africa reflecting changing population demographics and 
the influences of prenatal testing and termination of pregnancy.   
 
DS is characterised by typical dysmorphic features (see Figure 1.1 below and Table 1.4 on 
page 13), and is associated with an increased incidence of certain medical complications.  
 
 
Figure 1.1: Pictures of an infant with DS, showing typical facial dysmorphic features 
(Reproduced with the written permission of the parents) 
 
Some degree of mental, developmental and growth retardation is seen in all people with 
DS.  About 40% to 50% of individuals with DS have a congenital heart defect, most 
commonly endocardial cushion defects and ventricular septal defects (Freeman, Torfs, 
Romitti et al, 2009). Gastrointestinal abnormalities, such as oesophageal atresia, duodenal 
atresia, pyloric stenosis and Hirschsprung's disease, are found in more than 10% of 
individuals with DS.  All the children tend to be hypotonic and have delayed milestones.  
Acute lymphocytic leukaemia is more common in affected children, as are visual, 
urogenital and endocrine abnormalities (Jones, 2006).  The most common endocrine 
disorder associated with DS involves the thyroid gland (Pueschel, Jackson, Giesswein et 
al., 1991).   
31.2 THYROID HORMONES AND THEIR FUNCTION 
 
Under the regulatory control of the hypothalamus and the pituitary gland, the thyroid gland 
secretes hormones, principally thyroxine (T4) and triiodothyronine (T3), which regulate 
the rate of metabolism and affect the growth and rate of function of many other systems in 
the body.  Free T3 and free T4 (hereafter abbreviated as FT3 and FT4) are the biologically 
active components of the total T3 or total T4, respectively.  The production of T4 and T3 is 
regulated by thyroid-stimulating hormone (TSH), released by the thyrotrope cells in the 
anterior pituitary. The thyroid and thyrotropes form a negative feedback loop: TSH 
production is suppressed when the T4 levels are high, and vice versa. The TSH production 
itself is modulated by thyrotropin-releasing hormone (TRH), which is produced by the 
hypothalamus and secreted at an increased rate in situations of accelerated metabolism (see 
Figure 1.2) (Rossi, Caplin and Alter, 2005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Hypothalamic-pituitary-thyroid feedback.  
 
 
TRH
TSH
T4
HYPOTHALAMUS 
T3
- 
- 
PITUITARY GLAND
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Normal thyroid hormone levels are necessary for optimal growth and cognitive 
development and functioning.  Thyroid hormones play a crucial role as regulators of 
growth and skeletal development, puberty and metabolism (Rossi, Caplin and Alter, 2005). 
Specifically, in the central nervous system, thyroid hormones are important in neuronal 
migration and differentiation, activation of the sympathetic nervous system, myelination 
and regulation of gene expression of neuronal cells (Bernal and Nunez, 1995). 
1.3 THYROID DYSFUNCTION  
 
When thyroid function is normal, meaning that both the TSH and the FT4 are within 
normal limits, the patient is termed “euthyroid”.  Thyroid dysfunction can broadly be 
divided into two categories: hypothyroidism (underactive thyroid) and hyperthyroidism 
(overactive thyroid).  The diagnosis of thyroid dysfunction may be complicated by a few 
issues.  Firstly, the clinical symptoms may be very mild.  Secondly, on a biochemical level, 
one may encounter TFT results, which demonstrate seemingly paradoxical results, such as 
a low TSH level with normal FT4 and FT3 results, or an elevated TSH level with normal 
FT4 and FT3 levels (discussed further below).  Thyroid function can be labile, with 
hormone level shifts occurring over weeks or months.   Thyroid function tests may also be 
influenced by concomitant illness or drug administration (Rossi, Caplin and Alter, 2005). It 
is therefore important to keep all these elements in mind when interpreting TFT results. 
 
1.3.1 HYPOTHYROIDISM 
Hypothyroidism results from underproduction of the thyroid hormones FT4 and FT3.  
There are different forms of hypothyroidism, which differ by age of onset, biological 
mechanism and degree of abnormality of the other thyroid hormones in addition to the 
TSH (Rossi, Caplin and Alter, 2005).  Hypothyroidism in the newborn is termed congenital 
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hypothyroidism (CHT) and is discussed in more detail in section 1.3.1.3.   Hypothyroidism 
in older children and adolescents can have many causes (see table 1.1) (Hueston, 2001).   
 
Most cases (95%) of hypothyroidism in children are due to primary hypothyroidism or 
failure of the thyroid gland to produce thyroid hormones. These are typically associated 
with elevated levels of TSH and low levels of FT4 and FT3.  The remaining 5% of cases 
are due to central causes, also known as secondary and tertiary hypothyroidism, caused by 
pituitary gland or hypothalamic dysfunction, respectively (Hueston, 2001).  In these cases, 
the TSH can be low, normal or inadequately elevated for the degree of FT4 and FT3 
deficiency (Hueston, 2001).  Subclinical hypothyroidism (SCH) is a state of usually 
asymptomatic, mild thyroid failure, with normal levels of FT4 and FT3, and minimal 
elevation of TSH (Rossi, Caplin and Alter, 2005).   
 
Table 1.1: Causes of hypothyroidism in older children and adolescents* 
 
Autoimmune Hashimoto’s thyroiditis 
Iodine-related Deficient intake of iodine 
Excessive intake iodine/related substances 
Thyroid gland damage Infiltration into thyroid 
Radiation therapy 
Radioactive iodine therapy 
Thyroidectomy 
Congenital Late onset congenital hypothyroidism 
Thyroid dysgenesis 
Inborn errors of thyroxine synthesis 
General Hypothalamic-pituitary disorder 
Generalised thyroid hormone deficiency 
Drugs Several including thionamides, lithium, anti-convulsants, 
interferon alfa, tyrosine kinase inhibitors 
Dietary Goitrogen ingestion (eg cassava beans) 
Other/rare Histiocytosis X 
Cystinosis 
*Adapted from Hueston 2001 
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1.3.1.1 Primary Hypothyroidism  
Children with primary hypothyroidism have high serum TSH concentrations and low 
serum free T4 values. This biochemical presentation may be associated with clinical signs, 
such as lethargy, weight gain, dry skin, cold intolerance, constipation, delayed puberty, 
goitre, poor growth and delayed bone and dental age.  Short stature and intellectual 
deficiency are other invariable long-term sequelae, if the hypothyroidism is not treated 
(Rossi, Caplin and Alter, 2005).  For the purposes of this study, hypothyroidism as 
demonstrated by an elevated TSH with a corresponding decrease in FT4 will be referred to 
as overt hypothyroidism (OHT). 
   
1.3.1.2 Central Hypothyroidism 
Central hypothyroidism is caused by pituitary and/or hypothalamic dysfunction.  Of note, 
TSH levels are low or normal.  If the TSH is elevated, it is usually not to the degree one 
would expect relative to the FT4 and FT3 levels (Rose, Brown, Foley et al., 2006).  This 
may occur as a result of decreased stimulation of the anterior pituitary by TRH, or by 
deficient synthesis or secretion of TSH by the anterior pituitary.  In some cases, the lack of 
active TSH is a consequence of biologically ineffective TSH being secreted (Braverman 
and Utiger, 2005).  The clinical manifestations of central hypothyroidism are related to a 
deficiency of FT3 and FT4 and therefore are similar to primary hypothyroidism (Brown, 
2001). 
 
Patients with central hypothyroidism may have concomitant derangements in one or more 
pituitary hormones, including ACTH, gonadotrophin hormones (LH and FSH), growth 
hormone, and prolactin deficiencies.  If central hypothyroidism is caused by a functioning 
pituitary adenoma, other hormonal dysfunction may be present (Braverman and Utiger, 
2005). 
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1.3.1.3 Congenital hypothyroidism  
Congenital hypothyroidism (CHT) refers to hypothyroidism which is present from birth.  It 
occurs in 1 in 2000 to 1 in 4000 live births.  It is most commonly caused by dysgenesis 
(abnormal development) of the thyroid gland (85%).  Other causes include abnormalities of 
thyroid hormone synthesis, also known as dyshormonogenesis, central abnormalities 
(hypothalamic-pituitary axis defects) and peripheral defects (due to abnormalities in 
thyroid hormone metabolism, action or transport) (Rastogi and LaFranchi, 2010).  
Furthermore, CHT may be classified as transient (CHT which resolves) or persistent.  
There are several genetic syndromes, including Down syndrome, which are associated with 
increased prevalence of CHT (Rastogi and LaFranchi, 2010).  Table 1.2 summarises the 
main causes of CHT.  
 
Table 1.2: Causes of congenital hypothyroidism 
PRIMARY CHT 
Thyroid dysgenesis  
Thyroid dyshormonogenesis 
 
Ectopic gland, hypoplasia or hemiagenesis 
Impaired hormone production 
CENTRAL CHT 
Isolated TSH deficiency 
TRH abnormality 
 
Structural abnormality 
Other 
 
TSH β subunit gene mutation 
Deficiency of TRH, resistance to TRH, 
TRH receptor gene mutation 
Pituitary or hypothalamic lesion 
Rare genetic mutations resulting in 
abnormalities of the hypothalamic-pituitary 
axis 
PERIPHERAL CHT Resistance to thyroid hormone 
Hormone receptor or transporter 
abnormalities 
TRANSIENT CHT Maternal antithyroid medication ingestion 
Transplacental passage of TSH receptor 
blocking antibodies 
Iodine deficiency (maternal/neonatal) 
Congenital hepatic haemangioma 
OTHER Genetic syndromes 
*Adapted from Rastogi and LaFranchi, 2010 
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Normally, within the first half hour after birth, newborns experience a surge in TSH levels 
in response to the change in environmental temperature.  This rise in TSH can be 
accompanied by increased levels of FT4, especially in the first 48 hours.  Thus, testing for 
thyroid dysfunction in the first two days of life may not be routinely done (Rossi, Caplin 
and Alter, 2005).  However, in settings where newborns are discharged within 48 hours of 
birth, thyroid function is still tested but compared with cord blood TFT reference ranges 
(Dr George van der Watt – personal communication).   
 
Clinical features of hypothyroidism in the newborn are often non-specific, especially in the 
newborn, and may include decreased activity, increased sleep, difficulty feeding, 
constipation, prolonged jaundice, large fontanelles, macroglossia and hypotonia (Rossi, 
Caplin and Alter, 2005).  Congenital hypothyroidism (CHT) can be diagnosed within the 
first few days of life (usually between three and seven days) as is usually the case in 
countries where a Newborn Screening (NBS) protocol exists.   
 
1.3.1.4 Subclinical hypothyroidism  
Subclinical hypothyroidism (SCH) is defined by persistent elevation of TSH, while FT4 
remains normal (Rossi, Caplin and Alter, 2005).  It is called “subclinical” as there are often 
no clinically discernable features of hypothyroidism.  The diagnosis relies on the 
biochemical markers.   
 
 
1.3.2 HYPERTHYROIDISM 
Hyperthyroidism is diagnosed in the presence of a decreased TSH level.  The FT4 and FT3 
levels are typically elevated.  There may be associated clinical signs, such as inattention, 
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decreased sleep, heat intolerance, increased heart rate, frequent stools, poor weight gain, 
decreased school performance and personality changes (Rossi, Caplin and Alter, 2005). 
 
1.3.3 INTERPRETATION OF ABNORMAL THYROID HORMONE RESULTS 
When TFTs are performed, it is important to consider the entire hormonal profile, i.e. TSH 
and FT4 (with or without FT3), together with the clinical presentation.  The results should 
be compared to age-specific normal values.  Table 1.3 summarises the main differential 
diagnoses, which are considered to be associated with different abnormal TFT results 
(Wallach, 2000; Surks, Ortiz, Daniels et al., 2004; The Association for Clinical 
Biochemistry, British Thyroid Association, British Thyroid Foundation, 2006; Marshall 
and Bangert, 2008). 
 
Table 1.3: Differential diagnosis with abnormal thyroid function test results 
TSH Level FT4 Level Differential Diagnosis 
 
LOW LOW Suggests central hypothyroidism - TSH may be decreased, 
normal, or slightly elevated. Investigation for deficiencies in 
other pituitary hormones should be undertaken and may 
include: ACTH with cortisol, FSH, LH, oestradiol (female), 
testosterone (male), prolactin, growth hormone, and insulin-
like growth factor 1 (IGF1).  
Other non-thyroidal illness. TSH can be normal or low 
followed by rebound elevation during recovery from acute 
illness. FT4 can be normal, low, or high.  
LOW NORMAL May suggest mild hyperthyroidism.  
In non-thyroid illness, TSH can be normal or low followed 
by rebound elevation during recovery from acute illness. FT4 
can be normal, low, or high.  
Drugs which inhibit pituitary TSH secretion, including 
dopamine, dopaminergic agonists, glucocorticoids, cytokines, 
among others. 
Recent treatment of hyperthyroidism with anti-thyroid 
medication. 
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TSH Level  
 
HIGH 
FT4 Level  
 
HIGH 
Differential Diagnosis 
TSH-secreting pituitary tumour or a syndrome of resistance 
to thyroid hormone. Further endocrine investigation is 
indicated. 
Thyroxine replacement therapy (for possible 
hypothyroidism) taken shortly before test 
HIGH LOW Suggests primary hypothyroidism.  
Other causes include damage to the thyroid (autoimmune 
destruction/thyroidectomy/ radioactive iodine treatment). 
HIGH NORMAL Suggests subclinical hypothyroidism  
Other diagnoses include recovery from non-thyroid illness, 
poor adherence to thyroxine replacement therapy or its 
malabsorption. Drugs should also be considered.  
NORMAL LOW May be suggestive of central hypothyroidism  
Drugs (including phenytoin, rifampicin, carbamazepine, 
barbiturates) 
LOW HIGH Suggestive of hyperthyroidism.  
Other diagnoses: subacute thyroiditis during the initial stages 
of the disease; factitious thyrotoxicosis (from excessive intake 
of thyroxine) or iodine-related.  
 
 
 
1.3.4 THE SPECTRUM OF THYROID DYSFUNCTION IN DOWN SYNDROME  
Individuals with DS exhibit a wide range of thyroid dysfunction.  Clinical forms of 
hypothyroidism found in individuals with DS include congenital hypothyroidism (CHT), 
subclinical hypothyroidism (SCH), transient and primary hypothyroidism, thyroxin-
binding globulin deficiency and chronic lymphocytic thyroiditis (Coleman, 1994).  There is 
no evidence to suggest that children with Down syndrome are at greater risk of developing 
central hypothyroidism than the general population.  However, the diagnosis of thyroid 
dysfunction in DS is complicated by the overlap between thyroid-associated symptoms and 
clinical features of the syndrome, as well as the difficulty in interpreting TFT results from 
children with DS (Coleman, 1994).   
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Subclinical or “compensated” hypothyroidism (SCH) is the most common form of thyroid 
dysfunction in DS patients, being reported in 25-32% of patients (Rubello, Pozzan, Casara 
et al., 1995; Tüysüz and Beker, 2001).   
 
Hyperthyroidism, although rarer, also occurs more frequently in DS individuals than in the 
general population (Takahashi, Bordy, Sharma et al., 1979).  A study on the prevalence of 
hyperthyroidism in Catalonia, Spain revealed a figure of 6.5 cases per 1000 patients with 
DS.  This too, is higher than expected for the general population (Goday-Arno, Cerda-
Esteva, Flores-Le-Roux et al., 2009). 
 
1.3.5 PROPOSED CAUSES OF THYROID DYSFUNCTION IN DOWN 
SYNDROME 
The underlying pathological mechanisms responsible for thyroid dysfunction in individuals 
with DS are not well understood.  Several hypotheses have been proposed: 
 
1.3.5.1 Abnormal Thyroid Gland Development 
It has been postulated that defective migration and differentiation of thyroid cells 
during embryonic development and abnormal growth of the thyroid gland in fetal 
life, results in agenesis or hypogenesis of the gland (Gruneiro de Papendick, 
Chiesa, Bastida et al., 2002).  However, the cause of congenital hypothyroidism 
may not be entirely due to thyroid agenesis, as most patients have normal thyroid 
scans (Kennedy, Jones and Cuckle, 1992).   
 
1.3.5.2 An Auto-Immune Process 
Auto-immune thyroiditis may cause both SCH and OHT (Fort, Lifschitz, Bellisario 
et al., 1984; Ivarsson, Ericsson, Gustafsson et al., 1997).  Children with DS exhibit 
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an increased risk of autoimmune thyroiditis (Pueschel and Pezullo 1985; Sharav, 
Collins, Baab et al., 1988; Ivarsson et al., 1997).  Autoimmune thyroiditis has also 
been implicated in the pathogenesis of SCH in children with DS. (Rubello et al., 
1995; Konings, Van Trotsenburg, Ris-Stalpers et al., 2001).  The anti-thyroid 
antibodies implicated are directed toward thyroglobulin and thyroid peroxidise.  
Rubello et al (1995) observed a higher prevalence of SCH and anti-thyroid 
antibodies in DS patients compared with controls.  Patients with SCH, who had 
thyroid antibodies, tended to have a higher risk of developing overt hypothyroidism 
compared to thyroid-antibody negative individuals (Rubello et al., 1995).  Shawky, 
Elsedfy and Amer et al (2005) studied 40 Egyptian children with DS and compared 
their thyroid function results and thyroid antibody results to 40 children from the 
general population.  They found that the most common form of thyroid dysfunction 
in their DS study group was SCH (32.5%) compared to 12.5% in the control group.  
Also, 65% of DS children had thyroid antibodies, compared to 15% among 
controls.  Zori, Schatz and Ostrer et al (1990) studied 61 individuals with DS, aged 
5 months to 48 years, and sought to clarify the role of antibodies in DS thyroid 
dysfunction.  They, however, suggested that thyroid dysfunction in patients with 
DS occurs at all ages and is a “common heterogeneous disorder which cannot be 
solely explained on the basis of autoimmunity”. 
 
1.3.5.3 Delayed Maturation of the Hypothalamic-Pituitary Axis 
Delayed maturation of the hypothalamic-pituitary axis has been hypothesised as the 
probable cause of hypothyroidism (particularly SCH) in DS patients.  Sharav, 
Landau and Zadik et al (1991) demonstrated more exaggerated TSH responses to 
TRH in their patients with DS compared to controls. Oliveira, Longui and Calliari 
et al (2002) conducted a study on 14 children with DS, aged between 1.6 to 5.2 
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years (mean 3.2 years).  They compared the thyroid function in these patients to 16 
controls, and surmised that basal TSH levels were higher in the DS group, and that 
they displayed a more striking response after stimulation with TRH.  They 
concluded that “an abnormal pattern of TSH secretion occurred in patients with 
Down syndrome, possibly due to hypothalamic dysfunction”. 
 
1.3.5.4 Primary Thyroid Gland Abnormality in Neonates with Down Syndrome 
Van Trotsenburg, Kempers and Endert et al (2006) showed that neonates with DS 
can be mildly hypothyroid.  They proposed that this mild but persistent hypothyroid 
state could be primarily thyroidal in origin, although the exact mechanism is still 
unclear.   
 
1.3.5.5 Mutations in the TSH-Receptor Gene 
Mutations in the TSH-receptor gene have been postulated to cause thyroid 
dysfunction in individuals with DS.  However, Agretti, De Marco and Collecchi et 
al (2003) did not find inactivating mutations of the TSH-receptor gene in 12 
patients with DS who had elevated TSH levels.   
 
1.3.5.6 Genomic Imbalance due to Trisomy of Chromosome 21 
A DS-specific thyroid regulation disorder due to a genomic dosage imbalance 
caused by the extra chromosome 21, has also been suggested (Antonarakis, Lyle, 
Dermitzakis et al., 2004; Van Trotsenburg et al., 2006).  If this is the case, further 
studies are needed to delineate the loci and genes involved. 
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1.3.5.7 Decreased Bioactivity of TSH 
The bioactivity of TSH in DS individuals was questioned.  Konings et al (2001) 
found no evidence that children with DS have reduced bioactivity of serum TSH 
compared to euthyroid controls.   
 
1.3.5.8 Zinc Deficiency  
Zinc deficiency appears to be more frequent in DS patients, and can affect 
endocrine and immunological function.  Normalisation of serum zinc caused 
normalisation of TSH in a randomised control study in 25 children with DS.  After 
4 months of oral zinc supplementation, children with DS who had initially had 
higher levels of TSH compared to the 14 healthy controls, showed normalised TSH 
levels (Licastro, Mocchegiani, Zannotti et al., 1992).  This was later replicated in 
another study in children with DS (Bucci, Napolitano, Giuliani et al., 1999).  
However, Romano, Pettinato and Ragusa et al (2002) found no difference in the 
thyroid function of patients with DS who were zinc deficient, compared to those 
who were not (Romano et al., 2002).   
 
1.4 CLINICAL OVERLAP BETWEEN DOWN SYNDROME AND 
HYPOTHYROIDISM 
 
The diagnosis of hypothyroidism in individuals with DS can be difficult to establish 
clinically, as hypothyroid features can be masked by the clinical phenotype of the 
syndrome.  Indeed, many of the symptoms of hypothyroidism overlap with common 
features of DS (see Table 1.4).   
 
15 
 
Table 1.4: Comparison of Physical Features in children with DS and Hypothyroidism* 
*Adapted from Coleman (1994) 
 
One American study showed that 20% of community-based patients with DS, aged two to 
59 years, had previously undiagnosed overt hypothyroidism.  These patients had not 
complained of hypothyroid symptoms, nor had their doctors suspected hypothyroidism 
clinically (Friedman, Kastner and Pond, 1989).  Other studies confirm the incidence of 
undiagnosed overt hypothyroidism and SCH in newborns, children and adults with DS 
(Loudon, Day and Duke, 1985; Pozzan, Rigon, Girelli et al., 1990).    These findings occur 
in the presence of a national NBS programme in European countries, which includes 
thyroid testing for all children at birth (see Appendix A). 
 
Fifty Saudi Arabian children with DS (ages seven months to nine years) were studied by 
Abdullah and colleagues in 1994.  They found that 6% of the DS children had 
hypothyroidism, including two individuals who were symptomatic, but had not been 
previously evaluated for thyroid dysfunction or thyroid antibody status.  Thus, even though 
 Down syndrome  Hypothyroidism 
Head  Brachycephaly 
Intermediate fontanelle 
Normal  
Tongue  Protruding Large  
Nasal Bridge  Underdeveloped Underdeveloped 
Eyes  Upslanted palpebral fissures 
Epicanthic folds 
Brushfield spots (in blue eyes)
Normal  
Neck  Short  Short  
Heart  Murmur (mainly atrio-ventricular 
canal) 
Murmur (often non-specific) 
Abdomen  Umbilical hernia  Umbilical  hernia  
Neuromuscular  Hypotonia  Hypotonia  
Skin  Dry  Dry  
Extremities  Short hands and feet, 
transverse palmar crease,  
clinodactyly, wide sandal  
gaps, hyperextensible joints 
Short hands and feet 
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these children displayed “typical” signs of hypothyroidism, the diagnosis of 
hypothyroidism was not entertained as the signs were thought to be part of the DS 
phenotype (Abdullah, Salman, Al-Habib et al., 1994). 
 
1.5 EPIDEMIOLOGY OF THYROID DYSFUNCTION IN DOWN 
SYNDROME 
 
Since the early 1960’s, studies have been published documenting thyroid status in 
individuals with DS (Prasher, 1999).  Study design and populations tested have varied.  For 
example, Prasher (1995), Toledo et al (1997) and Noble et al (2000) used a cross-sectional 
study design, whereas the studies of Rubello et al (1995), Ivarsson et al (1997), Karlsson et 
al (1998) and Tüysüz and Beker (2001) were all longitudinal.   
 
A number of studies of thyroid function in DS have shown an increased prevalence of both 
congenital and acquired forms of hypothyroidism, as well as hyperthyroidism, albeit the 
latter to a lesser extent.  However, prevalence figures for thyroid dysfunction in DS vary 
according to the age ranges of patients and the population tested.   
Thyroid disorders have been reported to have a prevalence of 3 to 54% in people with DS, 
with the frequency of thyroid dysfunction increasing with age (Karlsson et al., 1998).   
However, it is estimated that the lifetime prevalence of hypothyroidism in DS is 30 to 50% 
(Prasher, 2006).    
 
Shaw and colleagues (2006) described a prevalence of hypothyroidism in the zero to one 
year age group as being 16.7% compared to 20% in the nine to 12 year group, reflecting an 
increase with age (Shaw et al., 2006).  Around 15% of adolescents with DS have 
hypothyroidism, with thyroid function decreasing with age (Pueschel et al., 1991).  
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Moreover, in a longitudinal study of 85 patients with DS (aged zero to 25 years), who did 
not have congenital hypothyroidism, Karlsson et al (1998) found that up to 15 years later 
30/85 (35%) had developed thyroid dysfunction: 28/30 (93%) had some form of 
hypothyroidism and 2/30 (7%) had hyperthyroidism. 
 
The prevalence of hypothyroidism in the newborn population of DS has been reported as 
0.7%, which is 28 times higher than the general population (Fort et al., 1984).  Reporting 
on statistics from the New York State Newborn Screening program, Fort et al (1984) 
described an incidence of congenital hypothyroidism in neonates with DS of 1 in 141 live 
births, compared to an incidence of 1 in 3000 to 1 in 4000 among healthy newborns.   
 
Summarised in table 1.5 are the findings from the significant studies conducted in both 
developed and developing countries over the past 30 years, which have investigated 
thyroid function in populations of infants and children with DS.  All studies have included 
a proportion of children with DS, although several have extended the studies to include 
adults with DS as well.   
 
The studies in table 1.5 show significantly increased frequency rates of the entire thyroid 
dysfunction spectrum associated with DS.  Most of the authors recommend regular (six 
monthly to annual) screening for thyroid dysfunction (with or without thyroid antibody 
testing) in their respective populations with DS.  Estimated frequency values vary. 
Differences between the studies can also be explained due to operational definitions 
employed and whether SCH was included under hypothyroidism, or given as a separate 
value.   However, evaluation of the studies presented in table 1.4 suggests that SCH 
accounts for the majority of thyroid dysfunction (frequency range of 5-88%).  
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Table 1.5: Summary of studies on thyroid dysfunction, which included children with DS 
over the last 30 years 
Author Year Country No. of 
patients 
Age 
ranges 
% of patients with 
thyroid dysfunction 
Fort et al  1984 USA 1130 3-16D 1.1% CHT (transient and persistent primary) 
Abassi and 
Coleman  1984 USA 206 <18Y 
8% OHT 
Pueschel and 
Pezzullo  1985 USA 151 3-21Y 
14% SCH 
6.6% OHT 
 
Loudon et al 1985 UK 116 9M-19Y 3.4% OHT  
Cutler et al  1986 USA 49 4M-3Y 
27% SCH 
2% OHT 
6% CHT 
2% hyperthyroidism 
Sharav et al  1988 Israel 147 4M-27Y 60% SCH  
Tirosh et al  1989 Israel 44 2-51Y 16% SCH  7% OHT 
Zori et al  1990 USA 61 5M-48Y 
39% SCH 
23% OHT 
3% hyperthyroidism 
Pozzan et al  1990 Italy 108 3M-38Y 
31% SCH 
5% OHT 
2% hyperthyroidism 
 
Pueschel et al  1991 USA 181 0-30Y 
8% SCH  
6% OHT 
 
Selikowitz et al 1992 Australia 132 4.58-17.08Y 
9.1% SCH 
3% OHT 
Abdullah et al 1994 Saudi Arabia 50 7M-9Y 
6% hypothyroidism 
 
Rubello et al  1995 Italy 344 N/S 32.5% SCH 
Toledo et al  1997 France 105 3M-20Y 
51.4% hypothyroidism 
(including SCH and 
OHT) 
Jaruratansirikul 
et al  1998 Thailand 112 <1Y 
15.2% some form CHT 
(overt and SCH) 
Karlsson et al 1998 Sweden 85 1-25Y 33% hypothyroidism 
2.4% hyperthyroidism 
Tüysüz and 
Beker 
2001 Turkey 320 5D-10Y 5% SCH (25.3% of 
those who had some 
form of thyroid 
dysfunction) 
1.8% CHT 
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Author Year Country No. of 
patients 
Age 
ranges 
% of patients with 
thyroid dysfunction 
Gruneiro de 
Papendick et al 
2002 Argentina 137 0.04-16Y 88% SCH 
6% OHT 
2.9% CHT 
3% hyperthyroidism 
Van 
Trotsenburg et 
al 
2003 The 
Netherlands 
284 4-7D 3.5% CHT 
Shawky et al 2005 Egypt 40 N/S 32.5% SCH 
Dias et al  2005 Brazil 169 1-16Y 39.6% SCH 
Mak et al 2006 China 351 0-19Y 22.5% SCH 
2% OHT 
2% CHT 
2.3% hyperthyroidism 
Shaw et al 2006 Nepal 32 1-12Y 12.5% SCH  
3.1% OHT 
Unachak et al 2008 Thailand 140 3D-14Y 32.9% SCH  
7.1% OHT 
2.1% hyperthyroidism 
 
Pascanu et al 2009 Romania 63 5D-18Y 27% SCH 
9.5% OHT  
1.6% CHT 
D:day; M:month; Y:year; CHT: congenital hypothyroidism; OHT: overt hypothyroidism; 
SCH: subclinical hypothyroidism; N/S: not stated 
 
1.6 THE SUBCLINICAL HYPOTHYROIDISM CONTROVERSY 
 
There is no disagreement among doctors about the management of overt hypothyroidism 
(increased TSH with low levels of FT4).  It is universally recognised that congenital 
hypothyroidism, especially, carries a high risk of severe developmental delay if not treated 
promptly (Rossi, Caplin and Alter, 2005).  The controversy arises with regard to SCH.  
This controversy is not confined to SCH in children with DS; it extends to normal children, 
pregnant women and even adults (Mc Dermott and Ridgway, 2001; Surks, Ortiz, Daniels et 
al., 2004; Papi, Uberti, Betterle et al., 2005; Surks, 2005; Gharib, Tuttle, Baskin et al., 
2005). 
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SCH is frequently encountered in general paediatric practice, but its clinical significance is 
widely debated.  There is unfortunately no consensus with regards to:  (i) the morbidity and 
clinical significance of SCH; (ii) whether to further investigate individuals with SCH, (iii) 
whether patients with SCH should be treated or not; and (iv) if treated, at which TSH levels 
treatment should be instituted.   
 
There are a few reasons for the lack of consensus surrounding the management of SCH.  
Firstly, there is a paucity of data on the natural history of SCH in children, and some 
clinicians are concerned that if left untreated, SCH would progress to overt 
hypothyroidism.  Individuals with SCH in the general population have a yearly risk of two 
to five percent of developing overt hypothyroidism.  This risk may be even higher in the 
presence of thyroid antibodies (Surks et al., 2004).  The clinicians caring for patients with 
DS are also faced with a paucity of data derived from patients with DS.  They too are 
required to extrapolate data from studies on normal children and normal adults, which may 
not be applicable to children with DS. 
 
Secondly, there are no large paediatric randomised controlled studies comparing outcomes 
in patients with SCH who were treated with thyroxine and those left untreated.  Thus, most 
clinicians have to rely on data from adult studies, which may also produce conflicting 
recommendations.    
 
Several recent studies have attempted to clarify the natural history of thyroid function in 
healthy children (Moore, 1996; Biondi and Cooper, 2008; Lazar, Frumkin, Battat et al., 
2009).  Lazar et al (2009) studied over 120 000 non-DS children aged between six months 
and 16 years, 3.3% of whom initially had an abnormally elevated TSH result (>5.5mIU/l).  
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They followed these children over a five year period.   Children with lower initial TSH 
levels (<7.5mIU/l), tended to experience spontaneous recovery, or their TSH levels 
remained constant. This was in agreement with previous studies, which suggested that 
SCH was a self-remitting process in childhood (Moore, 1996; Biondi and Cooper, 2008).   
Lazar et al (2009) identified female gender and higher TSH levels (>7.5mIU/l) as risk 
factors for sustained thyroid dysfunction, which warranted further investigation and 
monitoring.   
 
A similar study conducted on 122 children with DS was done by Gibson, Newton and 
Selby et al in 2005.  Their findings also suggest that SCH is a transient, self-limiting 
phenomenon (Gibson et al., 2005).  Gibson and colleagues, however, were only able to 
retest 20 children of the original 24 who had SCH and they found 14 (70%) had normal 
TSH levels.  Researchers would argue that this small sample size cannot be used to draw 
definitive conclusions regarding the natural history of SCH in the paediatric population 
with DS.    
 
Country-specific DS guidelines, such as those from the United Kingdom (UK), do not 
support the treatment of SCH (with a TSH level less than 10mIU/L), based on lack of 
evidence that treatment is beneficial in the paediatric population (Down Syndrome Medical 
Interest Group, 2005).   
 
Proponents of treatment of sub-clinical hypothyroidism offer as justification for their 
decision, the fact that decreased thyroid levels might be a confounding contributor to the 
poor growth and mental retardation in DS.  Increased TSH levels reflect the sensitivity of 
the hypothalamic-pituitary axis to small decreases in circulating thyroid hormone.  A FT4 
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level, while still mainly within the normal reference range, may actually be low for that 
particular patient, in the light of the increased TSH.  Some authors believe that SCH 
represents mild thyroid failure and is a clinically important disorder that has adverse 
clinical consequences and therefore should be treated in most, if not all, cases (McDermott 
and Ridgway, 2001).   Papi et al (2007) recommended that treatment should be instituted in 
all newborns with SCH to prevent possible detrimental sequelae: mental and growth 
retardation.   
 
Because some authors believe that SCH will eventually lead to overt hypothyroidism, 
Karlsson et al (1998) suggested that thyroxine replacement be encouraged even in cases of 
marginal hypothyroidism to prevent the development of a more severe hypothyroid state.  
Cutler and colleagues (1986) suggested that the isolated elevation of TSH in children with 
DS, even in the absence of thyroid antibodies, might be an early sign of primary 
autoimmune hypothyroidism. 
 
In 1998, Karlsson et al conducted a longitudinal study of 85 individuals with DS under the 
age of 25 years.  They treated 30 patients with DS, who were either diagnosed with SCH or 
OHT, and reported an increased growth velocity in seven patients with DS.  Other authors 
have recommended treatment for normal children and adolescents with SCH, and have 
linked treatment to significant improvements in height and development (Fatourechi, 2002; 
Cetinkaya, Aslan, Vidinlisan et al., 2003).   
 
Van Trotsenburg and colleagues (2003) described “mild” plasma TSH elevation as being 
extremely prevalent in individuals with DS: 80-90% in early infancy and 30-50% 
thereafter.  They studied 294 newborn samples from neonates with DS and found that the 
23 
 
decreased FT4 (normally distributed, but shifted to the left of the normal curve) and 
increased TSH levels pointed to a mild hypothyroid state in newborns with DS, and 
supported the existence of a DS-specific thyroid regulation disorder.  This lower thyroid 
hormone tissue availability might be disadvantageous for the already compromised brain 
development and somatic growth found in children with DS.  On the basis of the data from 
their study, suggesting that commencing treatment in young DS children may improve 
growth and development, they recommend that all DS newborns receive thyroxine 
treatment. 
 
A randomised control study on 196 patients was performed to test the benefit of thyroxine 
treatment in children with DS, and it showed that the patients receiving thyroxine showed 
less developmental delay and better growth than the patients who received placebos.  
These improvements in those receiving thyroxine were statistically significant (p<0.001) 
(Van Trotsenburg, Vulsma, Van Santen et al., 2005).  Although patients in this study were 
only followed-up for 24 months, and some exhibited some form of central nervous system 
derangement at re-examination, these findings were in contrast to an earlier study, which 
showed no significant difference between the DS group compared to a group of matched 
euthyroid controls with mental retardation of unknown cause, when treated with thyroxine 
supplements (Tirosh, Taub, Scher et al., 1989).  However, Tirosh et al only reported on 
seven patients, and their study evaluated patients shortly (eight to 24 weeks) after 
commencement of treatment.  They did not do any long-term follow-up on their original 
patients.  Longer-term studies are needed to evaluate the effects of thyroxine treatment on 
growth and development. 
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Other researchers view SCH as a distinct and relevant entity to be treated.  A study by 
Tüysüz and Beker (2001), recommends that every infant with DS be treated with thyroxine 
until the age of three years.  They felt that the advantage of this approach would be the 
prevention of OHT for those children whose thyroid function was not stable, and whose 
increasing TSH levels would eventually lead to a depressed FT4. 
 
1.7 ADVERSE EFFECTS OF HYPOTHYROIDISM 
 
One of the functions of thyroid hormone is to ensure optimal cardiac function.  In adult 
studies, neurobehavioural disturbances, cardiac dysfunction and dyslipidaemias have been 
reported in individuals with SCH (Mc Dermott and Ridgway, 2001).  Subclinical 
hypothyroidism (SCH) is proposed to have adverse effects on the cardiovascular system: 
directly by altering systolic and diastolic function and indirectly by negatively altering the 
lipid profile, by increasing both the total cholesterol and low-density lipoprotein (LDL) 
levels (Papi et al., 2007).  
 
Mao, Wang and Jiang (2008) showed that non-DS neonates with CHT have impaired 
cardiac function, which reverses with appropriate thyroxine supplementation.  They 
studied 50 Chinese neonates with CHT, aged 17-28 days, and provided evidence of 
significant left ventricular systolic dysfunction in neonates with CHT compared with age-
matched euthyroid controls (Mao et al., 2008).  No studies have been done to test the effect 
of CHT on the cardiac function in neonates with DS. 
 
The relationship between thyroid function and lipid status in a group of children was 
investigated by Nader and colleagues in 2010.  They found that children with TSH levels 
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between 2.5 and 5.0 mIU/L had higher triglyceride and insulin levels than those with lower 
TSH values (between 0.3 and 2.4 mIU/L).  Their results suggest that further study is 
needed to delineate the optimal thyroid hormone levels necessary to decrease the future 
risk of cardiovascular disease in children who have additional risk factors.   
 
Subclinical hypothyroidism (SCH) was suggested to decrease myocardial contractility and 
cardiac output (Biondi, Fazio, Palmieri et al., 1999; Di Bello, Monzani, Giorgi et al., 2000; 
Kahaly 2000).   Some studies in adults with SCH have shown that thyroxine replacement 
causes improved myocardial function (Biondi et al., 1999; Monzani, Di Bello, Caraccio et 
al., 2001).  Toscano, Pacileo and Limongelli et al (2003) performed a study on children 
with DS to ascertain the effects of SCH on myocardial structure and function.  They found 
that children with DS who have SCH are not at higher risk of having cardiac disease.  
However, their sample, which comprised 16 affected children with SCH and 25 matched 
euthyroid controls, was too small to draw any definitive conclusions.   
 
1.8 INTERNATIONAL SCREENING AND TREATMENT POLICIES 
 
As early as 1995, a consensus statement regarding the optimal medical care for individuals 
with DS was drawn up by experts from several countries (Pueschel, Annerén, Durlach et 
al., 1995).   As it is important to monitor potential determinants of morbidity and mortality 
to proactively improve the overall health and quality of life for individuals with DS, health 
surveillance protocols have been drawn up in several countries.   
 
Because hypothyroidism is treatable, early detection and treatment are essential in order to 
maximise the growth and cognitive abilities in this already impaired population.  Several 
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countries, including the UK and the USA, have protocols which describe the medical 
vulnerabilities and treatment of children with DS.   
 
The guidelines recommend a programme for regular screening, in order to identify 
treatable causes for a variety of symptoms, including hypothyroidism, which might 
otherwise be overlooked as being part of the DS presentation (UK - Down Syndrome 
Medical Interest Group, 2005); USA - Cunniff , Frias, Kaye et al., 2001; Bull, 2011).  
Appendix A is a summary of the main international guidelines as regards thyroid function 
testing in individuals with DS.   
 
Blood for TFT testing is traditionally drawn by routine venepuncture.  As children with DS 
have higher haematocrit levels compared to other children, a larger quantity of blood is 
often needed to carry out the TFT effectively (Stark, 1992).  Murphy, Philip and Macken et 
al (2008) explored the use of finger-prick blood spot TSH testing in pre-school children, 
and were able to verify the accuracy of the blood spot testing previously described by 
Noble, Leyland and Findlay et al (2000).  They propose finger-prick testing to be a viable 
alternative to routine venepuncture, and site several advantages of this approach, which 
include less trauma to the child and increased parental compliance with testing.  For the 
diagnosis of hyperthyroidism, however, Murphy et al (2008) advise not relying on 
bloodspot TSH alone.  
 
Hypothyroidism is one of the conditions included in the Newborn Screening (NBS) 
programmes in many parts of the world.  Blood specimens (usually heel-prick blood spots 
for TSH with or without FT4) are collected between two and seven days of age (optimally 
after 48 hours and before four days).  If abnormal, further confirmatory testing is 
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performed and thyroid hormone therapy is started if hypothyroidism is confirmed.  If 
therapy is started within the first two weeks after birth, cognitive development can be 
normalised in non-DS patients (Rossi, Caplin and Alter, 2005). 
 
While there are several DS thyroid screening recommendation protocols from around the 
world, standardised biochemical treatment thresholds for DS do not exist.  Clinicians are 
thus left to judge clinically when to institute treatment, which based on the DS phenotype, 
can prove problematic.  Reference ranges for TFT differ from laboratory to laboratory.  No 
DS-specific TFT reference ranges exist.  Instead, values are extrapolated from studies 
conducted on healthy children.  Many of the published guidelines only support treatment 
with thyroid hormone for DS patients where the TSH level is greater than 10mIU/L (UK - 
Down Syndrome Medical Interest Group, 2005).  Other authors have similarly noted that a 
TSH level greater than 10mIU/L after two weeks of age would be considered abnormal, 
and treatment should be instituted (Fisher, 2002; Rose et al., 2006).  However, the 
evidence for using this value in children is poor, and is extrapolated from adult studies.    
 
In addition, the Consensus Development Conferences sponsored by the Endocrine Society, 
the American Association of Clinical Endocrinologists (AACE) and the American Thyroid 
Association (ATA) recommend beginning thyroxine treatment when TSH values exceed 
10 mIU/L, based on the adverse effects on serum lipids and the risk of progression to overt 
hypothyroidism.  Therapy for lower levels of TSH remains controversial (Hollowell et al., 
2002; Surks et al., 2004). 
 
 
28 
 
1.9 SCREENING AND TREATMENT IN SOUTH AFRICA 
 
No standardised policy exists in South Africa as regards thyroid function screening, testing 
or treatment in individuals with DS.  None of the standard paediatric textbooks, like 
Nelson Textbook of Pediatrics or the South African Coovadia Textbook of Paediatrics 
mentions standard guidelines for the care of children with DS (Kliegman, Behrman, Jenson 
et al., 2007; Wittenberg, D.F., 2009), despite the fact that the American Academy of 
Pediatrics (AAP) first issued their DS guidelines in 2001 (Cunniff et al., 2001).   
South Africa, unlike other newly industrialised countries like Thailand, has not adopted the 
AAP guidelines as best practice for the care of the DS population.  The lack of a 
standardised protocol means that even children who are born in a tertiary hospital and have 
access to tertiary medical care, may never have their thyroid function tested.  Even less is 
known about thyroid screening in the non-academic, peripheral state hospital sector, where 
the majority of children with DS access medical care.    
 
In line with international practice, the clinicians in the Division of Human Genetics 
decided, in 2003, to test the thyroid function of all children with DS seen at the Genetic 
Counselling (GC) clinics.  Initial testing would take place at the first visit to the GC clinics, 
and annual testing would be performed thereafter, for as long as the children were seen at 
the GC clinics.  If the results were found to be abnormal, the patients were either retested 
or referred to a paediatric endocrinologist for further monitoring and treatment.  Upon 
discharge from the GC clinic, all patients with DS with normal TFTs are referred to their 
nearest hospital for further follow-up, including annual thyroid testing.   
 
South Africa does not have a national NBS programme.   Thus, congenital hypothyroidism 
is not diagnosed in the critical, treatment-sensitive period of the newborn’s life.  
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Furthermore, neonates with DS children will not be diagnosed with hypothyroidism, due to 
the lack of discriminating physical features to suggest that diagnosis.   
 
This makes the thyroid blood test screening of DS children even more important.  
However, even if the DS patients are tested for thyroid dysfunction, there are still no 
standardised South African guidelines as to when to treat, and whether or not to treat the 
controversial SCH. 
 
Outlined below are the treatment practices at the hospitals included in this study. 
 
1.9.1 CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL 
The consultants at CMJAH Paediatric Endocrine Clinic would like to assess all children 
with DS at their clinic as soon as the diagnosis of DS is made.  Almost all patients with DS 
are placed on thyroid hormone supplementation, unless they are overtly hyperthyroid.  
They note that thyroxine replacement is easy to prescribe, easy for the patients to ingest 
and easy to monitor by performing regular TFTs.  The justification for this blanket 
approach to supplementation is that it has been shown that increased levels of thyroid 
hormone may provide better cognitive and developmental outcomes, as seen in the short 
term study by Van Trotsenburg et al (2005).    The results of the study by Karlsson et al 
(1998) also found some evidence for improved growth velocity with treatment.  In seven 
out of eight children with DS, who had hypothyroidism and were treated with thyroxine, 
growth velocity in the year prior to commencing treatment was slower than after 
commencing treatment.  The growth velocity of these children was also better than that of 
age-matched euthyroid controls with DS.  Tüysüz and Beker (2001) recommend treating 
all infants with DS with thyroxine until the age of three years, to prevent progression to 
OHT.  In addition, no adverse effects have been noted in children with SCH, when treated 
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with thyroxine (Dr D. Segal- personal communication).  Children with DS are placed on 
the lowest dose of thyroxine necessary to keep their TSH levels close to 2 mIU/L, with a 
normal to high-normal FT4 level.  The patients are followed-up six to twelve monthly.  
The patients are monitored clinically for side-effects, and biochemically, in the form of 
repeat TFTs, for response to treatment (Dr D. Segal, personal communication).     
 
1.9.2 RAHIMA MOOSA HOSPITAL 
The consultants at the Paediatric Endocrine Clinic at RMH prefer to see all children with 
DS at their clinic, regardless of the initial TFT results.  Only patients with a TSH>10 
mIU/L are placed on thyroxine treatment, unless there is significant clinical evidence to 
suggest hypothyroidism at lower TSH levels, in keeping with the guidelines from the UK 
and USA.  The protocol is based on the premise that there is a lack of long-term benefit of 
thyroxine replacement in patients with DS who have TSH levels less than 10mIU/L (UK - 
Down Syndrome Medical Interest Group, 2005).The patients are followed-up at six to 
twelve month intervals and their response to treatment is monitored with repeat TFTs (Dr 
A Chiba, personal communication).     
 
1.9.3 CHRIS HANI BARAGWANATH HOSPITAL 
Unfortunately, the researcher was unable to obtain access to the data at the Endocrine 
Clinic at CHBH.  Therefore, sufficient information about the referral and treatment 
practices at that hospital is lacking. 
1.10 AIMS AND OBJECTIVES OF THE STUDY 
1.10.1 AIM:   
 To investigate thyroid function testing in a cohort of South African paediatric 
patients with DS 
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1.10.2 OBJECTIVES: 
 To document thyroid function test results in patients with DS attending the GC 
clinics between 2003 and 2008 
 To document how thyroid function in this cohort compares with results from 
international studies 
 To document referral and treatment patterns in this cohort 
1.11 LIMITATIONS OF THE STUDY 
 
Due to the differences in the biochemical analyses of the thyroid tests using different 
machines at the various laboratories, the results could not be pooled.  Statistical tests to 
prove variance were employed.  Thus the results from CHBH had to be analysed 
independently.    Additionally, a direct comparison between the TFT results in our study 
and the reference ranges was not directly possible for the following reasons.  Firstly, the 
reference ranges were derived using a German group of healthy children, and secondly, 
there was not enough information in the published study to draw the necessary distribution 
curves.  The referral and treatment practices from CHBH are not comprehensive, due to the 
lack of data made available from that hospital. 
1.12 UNIQUENESS OF THE STUDY  
 
This is the first study to document the frequency and range of thyroid dysfunction in 
African children with DS.  It is also the first attempt at describing the testing, referral and 
treatment policies at the Endocrine Clinics at two academic hospitals in South Africa.   
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2. PATIENTS and METHODS 
The study was a retrospective, file-based audit of all the thyroid function tests performed 
on children with DS at the three selected academic hospitals.  These hospitals, attached to 
the University of the Witwatersrand Medical School within the Greater Johannesburg area, 
were Charlotte Maxeke Johannesburg Academic Hospital (CMJAH), Chris Hani 
Baragwanath Hospital (CHBH) and Rahima Moosa Hospital (RMH). 
 
2.1 ASCERTAINMENT OF PATIENTS WITH DOWN SYNDROME 
 
The subjects in the study were all patients with DS seen at the Division of Human 
Genetics’ three main Genetic Counselling (GC) Clinics in the Johannesburg area.  The 
time period under investigation was a six year period from the beginning of 2003 until the 
end of 2008.  Patients seen within the Division were recorded in two separate databases.  
The first was a manual card system which was kept by the departmental secretary.  She 
added the names of individuals with a diagnosis of DS (indicated on the GC file 
facesheets), when she registered the files.  The second was an electronic Microsoft Access 
database which was updated with patient information, including diagnosis, at the time of 
patient billing. 
 
There were 468 children with a diagnosis of “Down syndrome”, “Down’s syndrome”, 
“Trisomy 21” and “T21” in the electronic Microsoft Access database, and 487 in the 
manual card database.  Reconciling the two databases yielded 446 patients with a 
registered diagnosis of DS.  Further investigation through examination of the Genetic 
Counselling (GC) files excluded 55 patients.  Patients were excluded for the several 
reasons.  Some were mothers of advanced maternal age (AMA), who were pregnant with a 
33
fetus with DS, and were incorrectly entered into the databases as DS patients.  Some had 
another syndrome, or “dysmorphic features”, incorrectly entered as DS on the databases.  
Others were from hospitals other than the three included in this study.  One was a case of a 
termination of pregnancy (TOP) for a fetus with DS. 
 
A sample of 391 patients was therefore used in the final analysis.  Figure 2.1 shows the 
individual number of patients obtained from each of the hospitals: CHBH, CMJAH and 
RMH, respectively, as well as the reasons for excluding patients, and the final number of 
patients which comprised the study sample. 
 
  
 
Figure 2.1: Composition of the sample (N=391)  
 
Reason for 
exclusion
AMA
Not DS
Other 
hospital
TOP for fetus 
with DS
Number of 
patients with DS
204
CHBH
10
3
1
0
190
172
CMJAH
12
5
23
1
131
70
RMH
0
0
0
0
70
446 
TOTAL
22
8
24
1
391
Total number of patients with DS included in the study = 391
Total number excluded =55
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2.2 METHODS 
2.2.1 CONSTRUCTION OF THE DATA COLLECTION SHEET 
Information relevant to this study was gathered from five sources: Genetic Counselling 
(GC) Clinic files, Paediatric Endocrine Clinic files, the National Health Laboratory Service 
(NHLS) Disa computer system at all three hospitals, the consultant paediatricians at the 
Paediatric Endocrine Clinics and the parents of the children with DS in certain cases. 
 
A data collection sheet was drawn up so that data relevant to the aims of the project could 
be systematically gathered.  The sheet (see Appendix C) consisted of 12 items, which 
included the following: demographic data (hospital, date of birth, age, race and gender), 
chromosome results, thyroid function test results (TSH and FT4 values and who requested 
the test) and referral and treatment information. 
 
2.2.2 DEMOGRAPHIC DATA  
Patient names, dates of birth, gender and ethnic group were gathered from the face sheets 
of the GC patient files.  To maintain confidentiality, all patients were then assigned a 
numerical code.  Only the researcher and her supervisors had access to the original patient 
name. 
 
2.2.3 CHROMOSOME RESULTS 
Chromosome results were generally available in the GC files.  Results were verified on the 
NHLS Disa computer system within the Division of Human Genetics. 
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2.2.4 THYROID FUNCTION TEST ANALYSIS, REFERENCE RANGES AND 
RESULTS 
Thyroid function testing at the NHLS laboratories at the teaching hospitals of the 
University of the Witwatersrand is undertaken using three different machines, although the 
biochemical assays are said to be similar.  At the CMJAH a Bayer Advia Centaur® 
Immunoassay System (Siemens Medical Solutions Diagnostics) is used.  Prior to 2005, all 
TFT assays from CHBH were sent to the CMJAH laboratory.  Subsequently, tests at 
CHBH were run on their own Roche cobas® 6000 analyser. All TFT samples from RMH 
are referred to Helen Joseph Hospital (HJH) and run on an Abbott Architect i1000SR 
machine.   
 
As of 2004, the NHLS follows the paediatric reference range recommendations of the 
Chemical Pathology Department at the University of Cape Town.  The recommended 
paediatric values were adopted from results obtained in a German study to determine TFT 
reference values in paediatric age groups (Hübner et al., 2002).  These recommendations 
were forwarded to and accepted by the Chemical Pathology Expert Committee (Dr George 
Van der Watt – personal communication).  The current NHLS TFT reference ranges are 
shown in Appendix B (Dr George Van der Watt – personal communication). 
 
For the purposes of the present study, only TSH and FT4 results were collected, as FT3 is 
rarely performed in routine TFT studies. The evaluation of FT3 is mostly useful in 
determining and monitoring hyperthyroidism; it is less useful in cases of suspected 
hypothyroidism (Rossi, Caplin & Alter, 2004).   
 
The TFT results were sourced directly from the NHLS Disa computer systems at CHBH, 
CMJAH and RMH.  Hardcopy printouts were available in most cases.  In addition, some 
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TFT results were available in the GC files: either as printouts or written in the GC clinical 
reports or letters.  In cases where the results were written in the file, results were verified 
and a hardcopy was printed from the NHLS system, where possible.   
 
Whether the patients were referred to a paediatric endocrinologist was recorded by the 
clinical geneticist or counsellor, in the GC file. 
 
If the TFT was found to be abnormal, the patient files at the Endocrine Clinics at CMJAH 
and RMH were reviewed to assess whether the affected patients were examined by the 
paediatric endocrinologist, and whether or not they were on treatment.  Unfortunately, the 
Endocrine Clinic files from CHBH could not be similarly accessed.   
 
In cases where patients with abnormal TFTs were not referred, or no record existed of 
them at the CMJAH and RMH Endocrine Clinics, attempts were made to contact them.  
This was undertaken by either phoning or writing to parents requesting that they bring the 
child to the hospital for a TFT and referral if necessary.   If patients were found to have no 
TFT result, attempts were made to contact the parents in the same way.  
 
2.2.5 INCLUSION AND EXCLUSION CRITERIA 
All TFTs performed on the patients with DS included in the study were considered as valid 
for inclusion, unless they were performed at times of admission to hospital, during 
concurrent illness or within the first 48 hours after birth.  Alterations in thyroid function 
test results are common in these situations, and can be misleading (Rossi, Caplin & Alter, 
2004).  In addition, TFT results were excluded if the patient was found to be on thyroid 
hormone replacement therapy at the time that the test was performed.   
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2.2.6 TREATMENT PRACTICES 
The consultant paediatricians in charge of the paediatric endocrine clinics at CMJAH and 
RMH were interviewed to assess the treatment methodologies at their respective hospitals.  
Information gathered directly from them included: 
 When they would prefer children with DS to be referred to their clinic 
 Whether they believe that SCH is a clinically significant entity 
 At which TSH levels children with DS are generally treated with thyroid hormone 
 What the justification for their approach was 
 The follow-up protocol at their clinics 
 
2.3 PROCEDURE 
 
Following the initial patient ascertainment, a comprehensive review of the GC files was 
undertaken.  Most of the demographic data was then added to the data collection sheet.  
Subsequently, TFT results were obtained from the three hospitals.  Upon review of the 
TFT results, the GC files of patients with abnormal results were again reviewed to verify 
referral information.  Referral practices were inferred from test results found on the 
hospital computer system, which were requested by doctors in the respective Endocrine 
clinics.  These test results were initially not added to the data set, as verification of 
treatment status needed to be undertaken first.  This was done by consulting the Endocrine 
Clinic files at CMJAH and RMH.  Information regarding treatment was collected 
simultaneously.  If patients who had abnormal results were not seen at the Endocrine 
Clinics, an attempt was made to contact the parents and retest or refer the patients as 
indicated.  Missing data included specific referral and treatment practices at CHBH, and 
not all CHBH patient data could be verified. 
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2.4 ANALYSIS 
2.4.1 OPERATIONAL DEFINITIONS 
For the purposes of this study, we defined the various forms of thyroid dysfunction as 
follows (all using the NHLS Paediatric reference ranges – see Appendix B): 
 Congenital Hypothyroidism: any patient with a high TSH level, which was 
demonstrated within the newborn period (first two to 28 days of life) 
 Subclinical Hypothyroidism: A high TSH in the presence of a normal FT4 
 Overt Hypothyroidism: A high TSH and a correspondingly low FT4 
 Hyperthyroidism: A low TSH and a high FT4 
 
2.4.2 STATISTICS 
Data from the completed data sheets were transferred into a Microsoft Excel spreadsheet 
for initial analysis.  After coding the responses, basic statistics including frequencies and 
the TFT distribution graphs were generated using Statistica (Version 10; StatSoft Inc, 
Tulsa, OK).  A statistician was consulted for assistance regarding the analysis of variation 
between the TFT distribution graphs from the three hospitals, so that a decision could be 
made whether to pool the results, or whether to analyse each hospital individually.  
Logistic regression was used to verify whether any of the demographic data had a 
significant influence on the TSH results.  Throughout, a p-value of less than or equal to 
0.05 was accepted as indicating statistical significance, unless otherwise stated.  Where 
relevant, the 95% confidence interval was used. 
2.5 ETHICS APPROVAL  
 
Ethics approval for this study was obtained from the Human Research Ethics Committee 
(Medical) of the University of the Witwatersrand: Certificate number M090710 (see 
Appendix D). 
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3. RESULTS 
The results from the main analyses performed on the collected data are presented in this 
chapter.  Collective data from all three hospitals were pooled for the initial analysis.  
Regarding the TFTs, an initial analysis of variance was performed to test whether there 
was a significant difference between the three different hospital groups.  Thus the TFT data 
from CHBH were analysed independently, while the data from CMJAH and RMH were 
analysed jointly.    
 
3.1 PATIENTS WITH DS INCLUDED IN THE STUDY 
 
A diagnosis of DS was confirmed in 391 patients.  All were included in the study. Figure 
3.1 shows the proportion of patients obtained from each hospital. 
 
 
Figure 3.1: Proportion of patients from each hospital (N=391) 
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3.2 CHARACTERISTICS OF THE SAMPLE 
 
The GC files of all 391 patients (100%) were located and reviewed.   
 
3.2.1 DEMOGRAPHIC DATA  
3.2.1.1 Gender distribution 
The sample of patients comprised approximately equal numbers of males and females, as 
shown in table 3.1.  
   
Table 3.1: Gender distribution by hospital (N=391) 
Hospital Male Female 
CHBH 100 (53%) 90 (47%) 
CMJAH 59 (45%) 72 (55%) 
RMH 34 (49%) 36 (51%) 
TOTAL 193 (49%) 198 (51%) 
    
 
3.2.1.2 Race distribution  
Black patients accounted for the majority of patients in the study (360/391; 92%).  The rest 
of the sample was made up of 3% white patients (11/391) and 4% coloured patients 
(16/391), and 1% of patients were of Indian descent (3/391).  
 
3.2.1.3 Age distribution of patients at first test 
The age distribution of the patients with DS at the time of their first TFT is shown in figure 
3.2.  All categories were chosen to correspond with those of the NHLS reference ranges 
(see Appendix B). 
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The majority (327/391; 84%) of patients had a TFT result available.  The age range of the 
patients at the time when the first TFT was performed was from one day to 6.8 years 
(average age 9 months).  Most (161/327; 49.2%) of the TFTs were performed between the 
ages of two and 12 months, with very few being done during the newborn period or after 
the age of five years.  These results are further clarified in figures 3.2 and 3.3.   
 
 
Figure 3.2: Age stratification of sample at initial TFT test (N=327) 
 
   
Figure 3.3: Age stratification in percentages of sample at first TFT test (N=327) 
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3.2.1.4 Age distribution of entire sample 
Although 391 patients were included in the study, several patients had more than one TFT 
result, which fulfilled criteria for inclusion in the study (i.e. tests performed at times of 
good health and patient not on any treatment).  The age distribution of the entire sample of 
516 TFTs is shown in Figure 3.4. 
 
Figure 3.4: Age distribution of entire sample of TFT results (N=516) 
 
The average age of the entire sample was 12.3 months (range one day to 7.67 years).  Once 
again, the majority of TFT samples were taken when the patients were between the ages of 
two months and one year.  The age distribution of patients from each of the three hospitals 
is shown in figure 3.5. 
 
Figure 3.5: Age distribution by hospital (N=516) 
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3.2.1.5 Chromosome results 
Most of the patients (356/391; 91%) had a full karyotype, and were thus sub-classified as 
having non-disjunction, translocation or mosaic DS.  The minority (28/391; 7%) had a 
PCR aneuploidy test only.  Seven patients (7/391; 2%) had no chromosome results.  In 
these cases the lack of a result was due to technical error, where the analysis was 
unsuccessful.  The tests were not repeated, and the diagnosis of DS remained clinical.   
 
Details of the chromosome results are shown in table 3.2.  Patients with non-disjunction 
made up the majority of those who had a full karyotype analysis, comprising 92.4% 
(329/356).  DS due to a translocation was found in 5.34% (19/356) of patients, and 2.25% 
(8/256) had mosaic DS. 
 
Table 3.2: Chromosome result (N=391) - distribution according to hospital 
 
 Non-
disjunction 
Translocation Mosaic PCR 
aneuploidy  
No result Total 
CHBH 165 12 4 7 2 190 
CMJAH 112 3 4 10 2 131 
RMH 52 4 0 11 3 70 
TOTAL 329  
(84%) 
19 
(5%) 
8 
(2%) 
28 
(7%) 
7 
(2%) 
391 
 
 
3.3 NUMBER OF PATIENTS TESTED  
 
Of the 391 patients in the study, 327 (84%) had at least one TFT performed.  The 
remaining 64 (16%) patients had no TFT result.  Of those who had no result, 83% (53/64) 
had never had their thyroid function tested, and 17% (11/64) either had a failed 
phlebotomy attempt, or there was insufficient blood submitted for analysis.  Details of all 
patients, by individual hospital, are shown in table 3.3.    
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Table 3.3: Number (N) of patients tested 
 
HOSPITAL (N) TFT result available No TFT/No result available 
CHBH (N=190) 165 25 
CMJAH (N=131) 106 25 
RMH (N=70) 56 14 
TOTAL (N=391) 327 (83.6%) 64 (16.4%) 
 
 
3.3.1 REPEAT TFTs PERFORMED 
Repeat TFTs are performed for a number of reasons: initial abnormal results, to monitor 
treatment outcomes or as a tool in thyroid function surveillance.  Altogether 113/327 
(35%) patients had at least one repeat TFT, which could be included in the study.  Twenty 
of these results were included after patients were contacted during the course of the study. 
 
Most of the repeat blood samples (60/113; 53%) were taken following an abnormal result.  
The repeat samples showed no uniform trend.  Several patients (19/113; 17%) initially had 
an abnormal result, but upon retesting the levels were found to be within the normal 
ranges.  Others (9/113; 8%) had variable results upon retesting, with more than one follow-
up result being either normal or abnormal.   
 
A proportion of patients (32/113; 28%) had consistently abnormal results.  Of these 32 
patients, six were tested during the neonatal period.  They all had repeat testing later in 
infancy, and their results were still abnormal.  In some cases, up to nine repeat TFTs were 
done on the same patient, all of which were abnormal.  There is a record of only two of 
these patients being started on treatment at CMJAH. The other CMJAH patients were not 
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referred to the Endocrine Clinic.  The rest of the patients were from CHBH, and there was 
no way to confirm their treatment status during the course of this study.   
 
There were 40 patients (40/113; 35%) who had more than one result, which remained 
consistently within the normal ranges.   
 
Very few patients (11/327; 3.4%) had a regular, yearly TFT performed.  Regular annual 
tests were performed by the doctors in the GC clinics (6/11; 54.5%), at the Endocrine or 
Developmental Clinic (3/11; 27.3%), or at a peripheral hospital (2/11; 18.2%).  Some 
patients (10/327; 3.1%) however, had ad hoc TFTs performed, presumably when they 
accessed healthcare. 
 
3.3.2 CONTACTING PATIENTS WITH NO TFT OR AN ABNORMAL RESULT 
In addition to the 64 patients who had never had a TFT (see table 3.3), 152 patients had 
TFT results outside of the reference ranges.  An attempt was made to contact these patients 
telephonically or in writing.  Contact could not be achieved with 60% of patients 
(116/194): the telephone contact numbers were no longer correct, they had moved house, 
there was no postal address available, or a combination of these factors applied.  They were 
thus lost to follow-up. 
 
Of the 40% (78/194) of patients who could be contacted: 20/78 (26%)  patients came for a 
repeat TFT (they were included with the other patients, who had repeat results in 3.3.1); 
11/78 (14%) parents informed us of the deaths of their infants/children; eight parents 
(10%) informed us that their children had regular TFT tests at the hospital closest to their 
homes; nine parents (11.5%) confirmed a follow-up appointment but did not arrive and 30 
patients (38.5%) did not respond to the letters sent to them. 
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Thus, of the 194 patients who had never been tested or had an abnormal TFT result 
requiring follow-up, a total of 155 (80%) were unable to be tested/re-tested. 
 
3.4 NUMBER OF THYROID FUNCTION TEST RESULTS 
COLLECTED 
 
In total, 536 results were collected from the 327 patients who had their thyroid function 
tested from each of the three hospitals.  Data available on the test results included the 
laboratory reference number, the name of the doctor who requested the test and the date the 
test was performed.  
 
Forty results were excluded from the study: 24/40 (60%) because they were performed at 
times of admission to hospital or concurrent illness, 13/40 (32.5%) as the patients were on 
thyroid hormone replacement therapy at the time the TFT was performed and 3/40 (7.5%) 
because they were performed within the first 48 hours after birth. 
 
As mentioned in 3.3.2, of the 78 patients who were contacted during the course of the 
study, 20/78 (26%) responded and subsequently had a TFT performed during the course of 
this study: 17 patients with no previous result and three patients with abnormal results had 
a repeat TFT.  
 
Therefore 516 results were included in the study: 485 full TFTs (TSH and FT4), 12 
individual TSH results and 19 individual FT4 results. 
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3.5 THYROID FUNCTION TEST REQUESTS  
 
The majority of tests were requested by the doctors at the Genetic Counselling (GC) 
Clinics (282/522; 54%), followed by the general paediatricians (183/522; 35%) and other 
paediatric specialists (57/522; 11%).  Figure 3.6 shows the proportion of tests requested by 
the main health professionals involved in the care of children with DS. 
 
 
Figure 3.6: Number and percentage of TFTs requested - by health care professional 
 
 
3.6 LABORATORY ANALYSIS OF THYROID FUNCTION TESTS 
 
All TFT results were checked using the laboratory number, which indicates the laboratory 
at which the test was analysed.  Several of the blood samples from CHBH patients were 
referred to the CMJAH laboratory for analysis.  Of the 262 tests performed on patients 
from CHBH, 159 were analysed at CMJAH’s laboratory.  In addition, six results from 
RMH patients were analysed at CMJAH.  All other RMH TFT blood specimens are 
referred to the HJH laboratory for analysis.  The total number of TFTs analysed by each 
hospital laboratory is presented in figure 3.7. 
279
(54%)
183
(35%)
54
(11%)
Origin of TFT request
Clinical Geneticist
Paediatrician
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Neurodevelopmental 
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Figure 3.7: Number of TFTs analysed by each hospital laboratory (N=516) 
 
For the purposes of the statistical analysis, one patient from RMH with a clearly outlying 
result, was excluded from further analysis and will be discussed separately (see section 
3.6.2.3 on page 49).  The following analysis was thus performed on 515 TFT results, which 
included 496 TSH results and 503 FT4 results. 
 
Many of the TFTs from patients at CHBH were analysed at CMJAH because doctors at the 
GC clinics suspected a discrepancy between results at CHBH compared to those from 
CMJAH.  This occurred in 2005, when a patient with DS had a TFT analysed at CHBH 
and a repeat TFT at CMJAH a week later.  The child had not had any illness at the time of 
initial testing at CHBH and no treatment was initiated between the two tests.  The initial 
CHBH result showed a TSH of 8.4 mIU/L (normal values: 0.4-5.25) and a FT4 of 14.8. 
(normal values: 10.8-19.0), compared to the repeat sample which was analysed at CMJAH, 
which showed a TSH= 5.0 (normal values: 0.4-5.25) and FT4= 16.2 (normal values: 10.8-
19.0).   
CHBH        
262 
CMJAH       
172
RMH         
82 
103 337 76 
159 6 
‐159  ‐6 
+  +
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The medians of both the TSH and FT4 results from each of the hospitals were generated 
independently.  They were then compared using an analysis of variance statistical test.  As 
both the TSH and FT4 groups were not normally distributed (see sections 3.6.2 and 3.6.3 
below), a non-parametric Kruskal-Wallis test was used.   
 
Initial investigation found that at least one of the hospitals was significantly different to the 
others (p<0.001).  Further study of these findings revealed that the TSH and FT4 results 
from CHBH were very significantly different to the results obtained from CMJAH 
(p<0.001) and RMH (p<0.00001).  See Section 3.6.1 for more details.  For this reason the 
TSH and FT4 results from CHBH were analysed separately. 
 
3.6.1 ANALYSIS OF VARIANCE BETWEEN THE HOSPITALS 
3.6.1.1 Thyroid Stimulating Hormone (TSH) Results  
The medians and means of the TSH results for the three hospitals were generated 
(presented in table 3.4).  Medians were preferred due to the non-normal distribution of the 
data, although, due to the high N-values, means were also calculated.   
 
Table 3.4: TSH valid number, means, standard deviations, medians, minimum and 
maximum values by hospital 
HOSPITAL TSH 
Number  
(N) 
TSH 
Means 
(mIU/L) 
TSH 
Standard 
Deviations 
TSH 
Medians 
(mIU/L) 
TSH 
Minimum 
(mIU/L) 
TSH 
Maximum 
(mIU/L) 
CHBH 99 8.26 6.59 6.30 0.95 41.05 
RMH 74 4.60 3.22 4.01 0.79 19.31 
CMJAH 323 5.80 4.21 4.64 0.38 27.83 
Combined 496 6.11 4.79 4.89 0.38 41.05 
 
The initial non-parametric analysis of variance of the medians showed a significant 
variance (p<0.05), indicating that the means of the TSH values from at least one of the 
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hospitals was statistically different from the other hospitals. Tables 3.5 and 3.6 present a 
detailed description of the analysis. 
 
Table 3.5: TSH: Kruskal-Wallis analysis of variance (results in red are significant at 
<0.005) 
TSH Kruskal-Wallis ANOVA by Ranks; TSH  
Independent (grouping) variable: HOSPITAL 
Kruskal-Wallis test: H ( 2, N= 496) =23.66211 p =0.00001 
Code Valid N Sum of Ranks Mean Rank 
CHBH 1 99 29994.00 302.9697 
RMH 2 74 14706.00 198.7297 
CMJAH 3 323 78556.00 243.2074 
 
 
However, further analysis using a paired-wise Mann-Whitney non-parametric test proved 
that the difference between the TSH results from CHBH and the other two hospitals was 
statistically significant (p<0.0005) (see Table 3.6).  Thus the TSH results from RMH and 
CMJAH could be pooled, but the data from CHBH had to be analysed separately.    
 
Table 3.6: TSH: Mann-Whitney test by hospital (results in red are significant at <0.05) 
 
variable 
Mann-Whitney U Test - by Hospital 
Marked tests are significant at p <0.05 
Rank 
Sum 
CHBH 
Rank 
Sum 
RMH 
U Z p-value Z 
adjusted
p-value Valid 
N 
CHBH
Valid 
N 
RMH 
TSH 10100.0 4951.0 2176.00 4.5608 0.000005 4.56092 0.000005 99 74 
 Rank 
Sum 
CHBH 
Rank 
Sum 
CMJAH 
U Z p-value Z 
adjusted
p-value Valid 
N 
CHBH
Valid 
N 
CMJAH
TSH 24844.0 64409.0 12083.0 3.6781 0.000235 3.67811 0.000235 99 323 
 
Additionally, when comparing only the TSH values greater than 10mIU/L, there was a 
significant statistical difference between the CMJAH and RMH group and the CHBH 
results (p<0.05). 
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3.6.1.2 Thyroid Hormone (FT4) Results 
A similar analysis was done for the FT4 medians, and they too were found to be 
statistically significantly different (p<0.05).  These results are presented in tables 3.7 and 
3.8. 
 
Table 3.7: FT4 valid number, means, standard deviations, medians, minimum and 
maximum values by hospital 
HOSP FT4 
N  
 
FT4 
Means 
(pmol/l) 
FT4 
Standard
Deviation 
FT4 
Medians 
(pmol/l) 
FT4 
Minimum 
(pmol/l) 
FT4 
Maximum 
(pmol/l) 
CHBH 100 17.30 4.397 17.15 3.00 31.20 
RMH 72 15.98 4.661 15.05 3.00 33.50 
CMJAH 331 16.23 3.355 16.00 3.00 30.10 
Combined 503 16.41 3.806 16.00 3.00 33.50 
 
 
 
Table 3.8: FT4: Kruskal-Wallis test (effects marked in red are significant at p <0.05) 
 
FT4 Kruskal-Wallis ANOVA by Ranks; FT4  
Independent (grouping) variable: HOSP 
Kruskal-Wallis test: H ( 2, N= 503) =8.158379 p =0.0169 
Code Valid N Sum of Ranks Mean Rank 
CHBH 1 100 28587.00 285.8700 
RMH 2 72 16226.00 225.3611 
CMJAH 3 331 81943.00 247.5619 
 
 
Once again, more detailed analysis illustrates that there is a significant difference between 
FT4 results from CHBH compared to the other two hospitals (p<0.05) (see Table 3.9).  As 
with the TSH results, CHBH FT4 data were analysed separately. 
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Table 3.9: FT4: Mann-Whitney test (effects marked in red are significant at p <0.05) 
 
 
Var 
Mann-Whitney U Test – by Hospital 
Marked tests are significant at p <0.05 
Rank 
Sum 
CHBH 
Rank 
Sum 
RMH 
U Z p-value Z 
adjusted
p-value Valid 
N 
CHBH
Valid  
N 
RMH 
FT4 9429.5 5448.5 2820.5 2.418 0.015611 2.41821 0.015598 100 72
 Rank 
Sum 
CHBH 
Rank 
Sum 
CMJAH 
U Z p-value Z 
adjusted
p-value Valid 
N 
CHBH
Valid  
N 
CMJAH
FT4 24207.5 68888.5 13942.5 2.388 0.016930 2.38840 0.016922 100 331
 
 
3.6.2 COMBINED CMJAH AND RMH TFT RESULTS 
A total of 336 thyroid function tests were analysed at the CMJAH laboratory and 76 
thyroid function tests were analysed at the Helen Joseph Hospital (HJH) laboratory, where 
all RMH samples are referred.  The combined total number of TFT results (N=412) 
included 397 TSH and 403 FT4 results. 
 
3.6.2.1 Combined CMJAH and RMH: TSH Results 
The results of the combined analysis of the TSH results from CMJAH and RMH are 
detailed in table 3.10. 
 
Table 3.10: TSH median, mode, valid N, minimum, maximum and standard deviations for 
CMJAH and RMH combined 
CMJAH 
& RMH 
Valid  
N 
Median 
(mIU/L) 
Mode 
(mIU/L)
Frequency 
of Mode 
Minimum
(mIU/L) 
Maximum 
(mIU/L) 
Standard 
Deviation 
TSH 397 4.38 4.18 4 0.38 27.83 4.06 
 
The distribution of TSH results of the two hospitals combined is shown in the histogram in 
figure 3.8, which demonstrates that the TSH values were not normally distributed 
(Shapiro-Wilk p<0.2).  The values are skewed to the left of the expected, calculated normal 
curve (red line).   
53 
 
 
CMJAH and RMH
Histogram: TSH
Shapiro-Wilk W=.81526, p=0.0000
 Expected Normal
-5 0 5 10 15 20 25 30
TSH (uIU/l)
0
50
100
150
200
250
N
o.
 o
f o
bs
.
 
Figure 3.8: Distribution graph for patient TSH results (combined CMJAH and RMH) (N=397) 
 
3.6.2.2 Combined CMJAH and RMH: FT4 Results 
The results for the combined analysis of the FT4 results from CMJAH and RMH are 
detailed in table 3.11. 
 
Table 3.11: FT4 results for patients from CMJAH and RMH combined 
 
CMJAH 
& RMH 
Valid  
N 
Median 
(mIU/L) 
Mode 
(mIU/L)
Frequency 
of Mode
Minimum
(mIU/L)
Maximum 
(mIU/L) 
Standard 
Deviation
FT4 403 15.90 14.80 10 3.00 33.50 3.62 
 
 
The FT4 distribution of the entire sample is also not a normal Gaussian curve (Shapiro-
Wilk p<0.2).  The histogram in figure 3.9 demonstrates this non-normal distribution, with 
skewing of the FT4 values to the left of the expected, calculated normal distribution (red 
line). 
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Figure 3.9: Distribution graph patient FT4 results (combined CMJAH and RMH) (N=403) 
 
 
3.6.2.3 A patient from RMH with an outlying result 
A 30 day old black female infant with DS, seen at RMH, had a TSH=100mIU/L (normal 
range: 0.16-8.48mIU/L) and a FT4=5pmol/l (normal range: 10.9-25.5pmol/l).  She was 
thus overtly hypothyroid and was started on thyroxine replacement after a follow-up blood 
test revealed a similarly abnormal result.  Due to her clearly outlying result, she was not 
included in the initial data analysis.  
 
3.6.2.4 Percentage of patients in each thyroid dysfunction category 
Table 3.12 summarises the range of thyroid dysfunction in the 412 results collected from 
201 patients with DS from CMJAH and RMH, combined.  The majority of the results 
indicated a normal or euthyroid state (60.9%).  The results indicate SCH in 110/412 
(26.7%) of results. 
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Table 3.12: Range of thyroid dysfunction in CMJAH and RMH results (N=412) 
Category Number of 
results 
CMJAH 
Number of 
results 
RMH 
Total (%) 
Euthyroid 
 
197 54 251 60.9%  
Congenital hypo- 
thyroidism 
(CHT) 
7 
†TSH>10= 6 
†TSH>ref= 1 
0 7 1.7%  
Subclinical 
hypo-thyroidism 
(SCH) 
99 
†TSH>10= 23 
†TSH>ref = 76 
11 
†TSH>10= 2 
†TSH>ref= 9 
110 
†TSH>10= 25 
†TSH>ref= 85 
26.7%  
 
Overt hypo-
thyroidism 
(OHT) 
7 
†TSH>10= 2 
†TSH>ref= 5 
1 
†TSH>10= 1 
 
8 
†TSH>10= 2 
†TSH>ref= 6 
1.9%  
 
 
Both TSH and 
FT4 increased 
5 
†TSH>10= 1 
4 
†TSH>10= 2 
9 
†TSH>10= 3 
2.2% 
Isolated 
decreased FT4 
9 4 13 3.2%  
Isolated 
increased FT4 
12 2 14 3.4%  
TOTALS 336 76 412 100% 
Total number 
abnormal¥ 
139 22 161 39.1% 
† “>10”: refers to a TSH value greater than 10mIU/L; “>ref” refers to a TSH greater than the upper limit of 
the reference range but less than 10mIU/L 
¥ “Abnormal” refers to all results which did not reflect a euthyroid state 
 
 
3.6.3 CHRIS HANI BARAGWANATH HOSPITAL 
A total number of 103 thyroid function tests were analysed at the CHBH laboratory: 96 full 
TFT’s (TSH and FT4), 3 isolated TSH and 4 isolated FT4.  Thus, in total, 99 TSH results 
and 100 FT4 results were available for further analysis. 
 
3.6.3.1 CHBH TSH results 
The median, mode, maximum, minimum and standard deviation values for the sample of 
99 TSH results from CHBH are shown in table 3.13. 
Table 3.13: TSH valid N, median, mode, minimum, maximum and standard deviations for 
CHBH 
CHBH Valid 
N 
Median 
(mIU/L) 
Mode 
(mIU/L)
Frequency 
of Mode 
Minimum
(mIU/L) 
Maximum 
(mIU/L) 
Standard 
Deviation 
TSH 99 8.26 multiple 2 0.95 41.05 6.59 
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The distribution curve for the CHBH TSH results is shown in figure 3.10.  The histogram 
illustrates that the distribution is not normally distributed (Shapiro-Wilk p<0.2), but rather 
shifted to the left of the calculated normal curve (red line). 
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Figure 3.10: Distribution graph for patient TSH results from CHBH (N=99) 
 
3.6.3.2 CHBH FT4 results 
Details regarding the median, mode, minimum, maximum and standard deviations of the 
sample of 100 FT4 results from CHBH are illustrated in table 3.14. 
 
Table 3.14: FT4 valid N, median, mode, minimum, maximum and standard deviations for 
CHBH 
CHBH Valid  
N 
Median 
(mIU/L) 
Mode 
(mIU/L)
Frequency 
of Mode 
Minimum
(mIU/L) 
Maximum 
(mIU/L) 
Standard 
Deviation 
FT4 100 17.15 multiple 4 3.00 31.20 4.39 
 
The distribution curve for the CHBH FT4 results is shown in figure 3.11.  The histogram 
illustrates that the distribution is not normally distributed (Shapiro-Wilk p<0.2), but rather 
shifted to the left of the calculated normal curve (red line). 
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Figure 3.11: Distribution graph for patient FT4 results from CHBH (N=99) 
 
 
3.6.3.3 Box and Whisker Plots for TSH and FT4 by hospital and gender 
The box and whisker plots for the TSH and FT4 values from the 2 hospital groups (CHBH 
and the combined CMJAH and RMH group) are shown in figures 3.12 and 3.13.  They 
graphically reflect the distribution of the TFT values according to gender and hospital.  For 
both TSH and FT4, the medians from CHBH are significantly higher. 
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Figure 3.12: Box and Whisker plot – TSH by hospital and gender 
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Figure 3.13: Box and Whisker plot – FT4 by hospital and gender 
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3.6.3.4 Percentage of CHBH patients in each thyroid function category 
Table 3.15 summarises the range of thyroid dysfunction of patients with DS from CHBH. 
Of the results which reflected some form of thyroid dysfunction, SCH was the most 
frequent, accounting for 36.9% of all results.   
 
Table 3.15: Range of thyroid dysfunction in CHBH results (N = 103)  
 
Category Number of results % 
Euthyroid 
 
44 
 
42.7%  
Congenital 
hypothyroidism 
(CHT) 
 
9 
 
†TSH>10 = 6 (67%) 
†TSH>ref = 3 (33%) 
8.7% 
Subclinical 
hypothyroidism 
(SCH) 
38 
 
†TSH>10 = 19 (50%) 
†TSH>ref = 19 (50%) 
36.9%  
Overt 
hypothyroidism 
(OHT) 
 
3 
 
†TSH>10 = 3 (100%) 
2.9%  
Both TSH and FT4 
elevated 
 
3 
 
†TSH>10 = 1 (33%) 
†TSH>ref = 2 (67%)
2.9%  
Isolated decreased 
FT4 
1 1%  
Isolated increased 
FT4 
5 
 
4.9%  
Hyperthyroidism 0 0 
TOTALS 103 100% 
 
Total number 
abnormal¥ 
59 57.3% 
 
† “>10”: refers to a TSH value greater than 10mIU/L; “>ref” refers to a TSH greater than the upper limit of 
the reference range but less than 10mIU/L 
¥ “Abnormal” refers to all results which did not reflect a euthyroid state 
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3.6.3.5 Frequencies of thyroid dysfunction in this cohort 
The frequencies of thyroid dysfunction noted in this cohort are outlined below.  Subclinical 
hypothyroidism (SCH) accounted for the majority of patients with abnormal TFT results.  
There were no patients with hyperthyroidism. 
 
SCH: Results compatible with a diagnosis of SCH formed 28.7% (148/516) of the sample; 
these were collected from 99 patients, giving an overall frequency of SCH of 25.3% 
(99/391).  A TSH greater than 10mIU/L was found in 46 results collected from 39 patients 
with SCH from all three hospitals.  Thus 39.4% of patients (39/99) with SCH had a TSH 
value greater than 10mIU/L. 
 
CHT: Of the 62 tests performed in the newborn period, 16 showed a high TSH value, 
compatible with CHT (25.8%).  In total 51 children were tested during the newborn period: 
12 had CHT, giving a frequency of 23.5% (12/51). 
 
OHT: OHT was found in 14/516 of the results.  These results were obtained from 14 
patients (14/391), giving an overall frequency of OHT in this cohort of 3.6%. 
 
3.7 EFFECT OF DEMOGRAPHIC VARIABLES ON THE TSH 
VALUES 
 
In order to evaluate whether any of the demographic variables had an effect on the TSH 
values, logistic regression was used.   The data from all three hospitals were categorised 
into two categories: TSH higher than 10mIU/L; and TSH lower than 10mIU/L but above 
the reference range’s upper limit.  The cut-off of 10mIU/L was used because it is a 
common treatment-initiating threshold.  Only the results from the age category analysis 
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were significant.  Neither race nor chromosome results seems to have an effect on the TSH 
level (p>0.05).  Gender, although also not significant, is discussed in more detail in 3.7.2 
below.   
 
3.7.1 THE INFLUENCE OF AGE CATEGORY 
The age categories chosen were according to those used in the reference ranges (see 
Appendix B).  Hence, the age categories used for the analysis were as shown in Table 3.16: 
 
Table 3.16: Age categories used in the analysis 
  
Reference range age Age category used for analysis 
1- 3 days 1 
4 - 30 days 2 
31 - 60 days 3 
2 months-1 year 4 
1 - 5 years 5 
6 -10 years 6 
 
The results of the logistic regression show that age category 5 (one to five years) was 
significantly different from the other categories. Calculating the exponents of the estimates 
generated, allowed the calculation of odds ratios.  A child in age category 5 (one to five 
years) was 0.61 times less likely to have a TSH greater than 10mIU/L than a child in age 
category 1 (one to three days) (estimate = 0.93423; odds ratio=0.39; 95% confidence 
intervals 0.781 to 0.198) (p= 0.0077)).  Therefore, a very young child is more likely to 
have a raised TSH compared to older children. 
 
3.7.2 THE INFLUENCE OF GENDER 
Lazar et al (2009) identified female gender as a risk factor for thyroid dysfunction in the 
general paediatric population.  Table 3.16 reflects the number of abnormally high TSH 
values, according to age group and gender for all three hospitals.  The results show that 
62 
 
more results were available from male patients, and that proportionally more males had a 
TSH level greater than the upper limit of the reference ranges (39.6% versus the female 
30.9%) and a larger proportion of males had TSH values above 10mIU/L (13.9% versus 
10.7% in the female group). 
 
Table 3.17: Number of abnormal TSH results by gender and age category 
 
AGE 
CATEG. 
GENDER 
 
 
Total 
number 
of results 
from 
males 
MALES WITH 
INCREASED TSH 
Total 
number 
of results 
from 
females  
FEMALE WITH  
INCREASED TSH 
TSH>ref
range 
TSH>10 
mIU/L 
TSH>ref 
range 
TSH>10 
mIU/L 
Total 
TSH>10 
mIU/L 
1 8 4 4 2 1 1 5 
2 31 12 7 24 2 2 9 
3 26 11 4 37 10 5 9 
4 122 40 16 114 34 12 28 
5 81 39 7 63 26 5 12 
6 5 2 0 3 2 1 1 
TOTAL 273 108 
(39.6%) 
38 
(13.9%) 
243 75 
(30.9%) 
26 
(10.7%) 
64  
(12.4%) 
 
Logistic regression also revealed no significant difference between males and females.  
The analysis revealed an upper and lower confidence interval (-0.09978 to 0.43113) which 
included one, and a p-value of 0.22. 
 
3.8 REFERRAL INFORMATION  
 
Some patients had repeat tests, and if the repeat tests fell into the same category of thyroid 
dysfunction, the patient was counted only once.  The number of patients reflects those who 
were ever categorised into the various classes of thyroid dysfunction. 
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3.8.1 CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL 
In summary, 139 TFT results analysed at CMJAH fell outside of the reference ranges.  A 
total of 99 of these results were collected from 56 CMJAH patients.  The rest of the results 
were collected from CHBH and RMH patients, and will be discussed later.   
 
SCH: Of the 99 results classified as SCH, which were analysed at CMJAH (see Table 
3.12), 59 were collected from 35 CMJAH patients.   
 A proportion of the results (15/59; 25.4%) reflected a TSH value greater than 
10mIU/L.  These results were collected from 10 patients, six of whom (6/10; 60%) 
were subsequently started on thyroxine replacements therapy, either at the 
Endocrine Clinic at CMJAH or at another clinic/hospital (Developmental Clinic at 
CMJAH, Tembisa Hospital or Edenvale Hospital).  The other four patients (4/10; 
40%) were not referred. 
 The majority of results (44/59; 74.6%) indicated abnormally elevated TSH levels 
(above reference range but <10mIU/L).  These were collected from 25 patients, 
nine of whom (9/25; 36%) were on treatment at the Endocrine Clinic at CMJAH or 
the Developmental Clinic.  There were two patients (2/25; 8%) who have their 
thyroid function checked annually at the Cardiac Clinic.  They have not been 
referred to the Endocrinologists or started on treatment.  A single patient (1/25; 4%) 
was referred to the Endocrine Clinic but did not attend the appointment and 13 
others (13/25; 52%) were not referred to the Endocrine Clinic. 
 
OHT: Of the seven results classified as OHT, which were analysed at CMJAH (see Table 
3.12), five were collected from five CMJAH patients.  The rest of the results were 
collected from CHBH and RMH patients, and will be discussed later.   
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 TSH values greater than 10mIU/L were found in two patients (2/5; 40%).  Both 
patients (100%) are on thyroxine replacements therapy at the Endocrine Clinic at 
CMJAH. 
 The other three patients (3/5; 60%) had abnormally elevated TSH levels (above 
reference range but <10mIU/L).  Of these, only one (1/5; 20%) was on treatment at 
the Endocrine Clinic at CMJAH.  The other two (2/5; 40%) were not referred to the 
Endocrine Clinic. 
 
CHT: Of the seven results classified as CHT, which were analysed at CMJAH (see Table 
3.12), five were collected from five CMJAH patients.  The rest of the results were 
collected from CHBH patients, and will be discussed later.   
 TSH values greater than 10mIU/L were found in three patients (3/5; 60%).  All 
three patients (100%) are on thyroxine replacements therapy at the Endocrine 
Clinic at CMJAH  
 The other two patients (2/5; 40%) had elevated TSH levels (above reference range 
but <10mIU/L).  Both were not referred to the Endocrine Clinic during the neonatal 
period.  These patients were retested at age four and seven months, respectively, 
and were still hypothyroid.  They were subsequently referred to the Endocrine 
Clinic at CMJAH and are on thyroxine treatment. 
 
Other abnormal results: There were further abnormal TFTs, which included 11 results from 
11 patients were classified as having isolated elevated FT4, isolated decreased FT4 or 
elevated TSH with an elevated FT4.  None of these patients were referred to the Endocrine 
Clinic. 
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3.8.2 RAHIMA MOOSA HOSPITAL 
There were 22 abnormal results analysed at HJH, all from RMH patients.  Additionally, 
two abnormal results from RMH patients were produced from the CMJAH laboratory.  
These abnormal results were collected from 18 RMH patients 
 
SCH: While 12 results were classified as SCH (11 from RMH and 1 from CMJAH), these 
were collected from eight RMH patients.   
 Of the 12 results, two had TSH values greater than 10mIU/L (2/12; 16.7%).  These 
were collected from two patients:  both patients are on thyroxine replacements 
therapy at the Endocrine Clinic at RMH.   
 The other ten results (10/12; 83.3%) showed elevated TSH levels (above reference 
range but <10mIU/L).  These were collected from six patients.  A single patient 
(1/6; 16.7%) was on treatment at the Endocrine Clinic at RMH.  The other two (2/6; 
33.3%) have their thyroid function checked annually but have not been started on 
treatment.  A further three patients (3/6; 50%) were not referred to the Endocrine 
Clinic. 
 
OHT: The two results classified as OHT (one from RMH and one from CMJAH), were 
collected from two RMH patients.  One patient (50%) had a TSH greater than 10mIU/L 
and is on treatment at the Endocrine Clinic at RMH.  The other patient was not referred. 
 
Other abnormal results: A further eight results from eight patients were classified as having 
isolated elevated FT4, isolated decreased FT4 or elevated TSH with an elevated FT4.  Of 
those with both elevated values, two patients had TSH levels greater than 10mIU/L. None 
of these patients were referred to the Endocrine Clinic. 
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3.8.3 CHRIS HANI BARAGWANATH HOSPITAL 
There were 59 abnormal results analysed at CHBH.  Additionally, 44 abnormal results 
from CHBH patients were analysed at the CMJAH laboratory, making a total of 103 
abnormal results.  These abnormal results were collected from 78 CHBH patients. 
 
SCH: It was possible to classify 77 results as SCH (38 from CHBH and 39 from CMJAH).  
These results were collected from 56 CHBH patients.   
 TSH values greater than 10mIU/L were reflected in 37 results (37/77; 48.1%).  
These were collected from 27 patients:  A few patients (4/27; 14.8%) were assessed 
at the Endocrine Clinic at CHBH and are on thyroxine replacement therapy.  A 
further three patients (3/27; 11.1%) were referred to the Endocrine Clinic, but it is 
not clear whether they are on treatment.  A single patient (1/27; 3.7%) was referred 
to Natalspruit Hospital but it is not clear whether this patient is on treatment.  
Additionally, three patients (3/27; 11.1%) had a repeat TSH, which were found to 
be within the normal range, and they were thus not referred.  The rest of the 
patients (15/27; 55.6%) were not referred to the Endocrine Clinic, and 1/27 (3.7%) 
had no available referral information.    
 The majority of the results (40/77; 51.9%) showed elevated TSH levels above 
reference range but <10mIU/L.  These were collected from 29 patients.  The 
majority of them (22/29; 75.86%) were not referred to the Endocrine Clinic.  
Genetic counselling (GC) clinic records from two patients (2/29; 6.9%) showed that 
they were on treatment at the Endocrine Clinic.  A single patient (1/29; 3.45%) was 
referred to the Endocrine Clinic but didn’t attend the appointment, according to the 
parents.  A further four patients (4/29; 13.79%) were referred but it is not clear 
whether or not they are on treatment.   
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OHT: The six results classified as OHT (three from CHBH laboratory and three from 
CMJAH laboratory), were collected from six CHBH patients.   
 Of the six patients, four (4/6; 66.7%) had a TSH greater than 10mIU/L.  Of these, 
3/4 (75%) patients are on treatment at the Endocrine Clinic at CHBH, and 1/4 
(25%) was not referred.   
 There is no referral or treatment information available on the other 2/6 (33.3%) 
patients who had TSH values less than 10mIU/L. 
 
CHT: Of the 11 results classified as CHT, nine were analysed at CHBH and two at 
CMJAH.  They were collected from 7 CHBH patients 
 Those patients with TSH values greater than 10mIU/L formed the majority (5/7; 
71.4%).   
 The other two patients (2/7; 28.6%) had elevated TSH levels (above reference 
range but <10mIU/L):  
Referral and treatment information on these patients remain unavailable, as the CHBH 
Endocrine Clinic files could not be accessed (see Limitations section 1.11) 
 
Other abnormal results: Nine patients (nine results) were classified as having isolated 
elevated FT4, isolated decreased FT4 or elevated TSH with an elevated FT4.  There is no 
referral or treatment information available on these patients. 
 
 
3.8.4 SUMMARY OF PATIENT REFERRAL AND TREATMENT 
Tables 3.18 and 3.19 provide summaries of the referral practices for patients with elevated 
TSH values.  These include patients with SCH, CHT, OHT and those who had elevated 
levels of both TSH and FT4. 
68 
 
Table 3.18: Summary of referral practices by hospital for patients with TSH>10mIU/L  
Hospital TSH > 
10mIU/L (N) 
Number on 
treatment (N) 
(%) 
Number not on 
treatment (N) 
(%) 
Number not 
referred (N) (%) 
CHBH 37 7* (18.9%) Unknown 16* (43.2%) 
CMJAH 15 11 (73.3%) - 4 (26.7%) 
RMH 5 3 (60%) - 2 (40%) 
(* indicates number of patients for which information is available.  Total will not equal 100%) 
 
Table 3.19: Summary of referral practices by hospital for patients with TSH results above 
reference range but <10mIU/L 
Hospital TSH above 
reference 
range but 
< 10mIU/L (N) 
Number on 
treatment (N) 
(%) 
Number not on 
treatment (N) 
(%) 
Number not 
referred (N) (%) 
CHBH 46 2 (4.35%)* Unknown 22 (47.8%)* 
CMJAH 30 10 (33.3%) 3 (10%) 17 (56.7%) 
RMH 7 1 (14.29%) 2 (28.57%) 4 (57.14%) 
(* indicates number of patients for which information is available.  Total will not equal 100%) 
 
 
3.8.5 SUMMARY OF SIGNIFICANT RESULTS 
3.8.5.1 Demographics 
 The sample comprised 391 children with DS, most of whom (49%) were seen at 
CHBH.   
 The majority of the children were black (92%) and there were equal numbers of 
males and females.   
 Most of the patients were aged between two and twelve months, with few falling 
into the neonatal and older age groups.   
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3.8.5.2 TFTs Performed 
 84% of the 391 children with DS in this study had at least one TFT performed.   
 Most of the TFTs (54%) were requested by the doctors in the GC clinics.   
 A total of 516 TFT results were collected.   
 The majority of TFTs (336/516; 65%) were analysed at CMJAH. 
 There was a significant difference between results obtained from CHBH and the 
other two hospitals (p<0.005). 
3.8.5.3 Thyroid Dysfunction Spectrum 
 A wide spectrum of thyroid dysfunction was represented in this cohort, with the 
noticeable exception of hyperthyroidism.   
 The results collected (295/516; 57.2%) mostly reflected a euthyroid state, but a 
large proportion (148/516; 28.7%) fell into the SCH category.  These SCH results 
were collected from 99 patients, or 25.3% of the patients in the study. 
 There were equal proportions of male and female patients with TSH levels above 
10mIU/L.  
3.8.5.4 Referral and Follow-Up 
 A large proportion of patients (155/190; 84%) could not be contacted during the 
course of the study, and thus repeat TFTs could not be performed on those with 
abnormal initial TFTs. 
 Several neonates with high TSH results, and therefore, CHT, were not referred to 
the Endocrine Clinics, and were therefore not started on treatment in the neonatal 
period. 
 More than a third of all patients with high TSH results were not referred to the 
Endocrine Clinics for further management. 
 All the patients from CMJAH and RMH with TSH levels greater then 10mIU/L, 
who were referred to the Endocrine Clinics, were receiving thyroxine treatment. 
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 Little information was available about the referral and treatment practices at 
CHBH. 
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4. DISCUSSION 
DS is the most common viable chromosomal abnormality and children with DS form a 
substantial proportion of the patients seen in the GC clinics at the three academic hospitals 
in Johannesburg.  All the records of the 391 children with DS, who were seen during the 
six year period between 2003 and 2008, were traced.  Significant results obtained from the 
data analysis presented in Chapter 3 will be discussed. 
 
4.1 DEMOGRAPHIC FACTORS 
 
The majority (92%) of children with DS seen in the GC clinics are black, reflecting the 
demographics of the Greater Johannesburg area, where the study took place.  An additional 
explanation for the fewer numbers of white, coloured and Indian children could be related 
to economic and logistic factors.  Firstly, many children may be assessed and managed in 
the private health care system as opposed to the state system.  This study did not include 
children seen at the private GC clinic in Johannesburg, but had it done so, the demographic 
profile of the cohort may have changed.  Secondly, women of other ethnicities may have 
greater access to more sophisticated antenatal care, fetal screening, prenatal testing and 
termination of pregnancy, which may influence the birth rates of babies with DS among 
other ethnicities.     
 
Most children with DS referred to our GC clinics were aged two to twelve months, 
corresponding to the TFT reference range age category three (see Table 3.16 and Appendix 
B).  There was a noticeable paucity of newborns assessed and tested for thyroid 
dysfunction, despite many having had their diagnosis of DS confirmed within the neonatal 
period, before referral to the GC clinics. Also, children older than twelve months with DS 
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were under-represented, due to the fact that most children with DS are discharged from the 
GC clinics as soon as the genetic counselling of the family and the basic health supervision 
has taken place.  Repeat TFTs then become the responsibility of non-genetic health care 
professionals. 
 
During the period between 2003 and 2008, almost half (49%) of the patients with DS were 
seen at CHBH.  This is consistent with general expectations, as the GC clinic at CHBH is 
the largest clinic run by the Division of Human Genetics.   
 
4.2 CHROMOSOME RESULTS  
 
There were significantly fewer PCR aneuploidy tests performed than anticipated.  Most of 
the children with DS had a full karyotype.  This figure may be a reflection of the postnatal 
DS testing protocol at the time (2003-2008).  Prior to 2008, all children suspected of 
having DS had blood taken for a full karyotype analysis.  After 2008, PCR aneuploidy was 
introduced as the investigation of choice for postnatal confirmation of DS (Professor A. 
Christianson- personal communication). 
 
Altogether, 92.4% of the children had Trisomy 21 due to non-disjunction, as seen on the 
full karyotype analyses.  A proportion of the 7% who had a PCR aneuploidy positive 
result, would also be expected to have the non-disjunction type of DS, although the PCR 
aneuploidy cannot discriminate between non-disjunction DS, translocation DS or mosaic 
DS.  The proportion of patient with mosaic DS (2.25%) is similar to the quoted 
international figures (2.4%) (Thuline and Pueschel, 1982), but our frequency of 
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translocation DS is slightly higher: 5.34% compared to 3.3% internationally (Thuline and 
Pueschel, 1982).   
 
However, this cohort comprised a relatively small sample size, and larger studies are 
needed to more accurately describe the frequency rates of each subtype of DS in the South 
African population. 
 
4.3 NUMBER OF PATIENTS TESTED  
 
The majority (327/391; 84%) of the patients with DS had their thyroid function tested, 
while 16% never had a TFT.  More than half (279/516; 54%) of the TFTs were requested 
by the doctors in the GC clinics, compared to 35% (183/516) performed by the general 
paediatricians and 11% (54/516) by other health professionals, mainly the paediatric 
cardiologists and the neurodevelopmental paediatricians.  This finding illustrates good 
compliance amongst the doctors within the Division of Human Genetics in following the 
departmental policy to screen each child with DS for thyroid dysfunction.    
 
The Developmental Clinics at both RMH and CMJAH seem to be active in screening for 
thyroid dysfunction.  The Developmental Clinic at CMJAH performs thyroid tests at least 
annually on all their patients with DS, and also initiates treatment and monitoring.  Most of 
these children are not referred to the Endocrine Clinic, but are treated and monitored at the 
Developmental Clinic (Prof Lorna Jacklin - personal communication).  The study did not 
include a review of the Developmental Clinic files, and there may be more patients treated 
and managed there than were recorded.   
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A number of TFT results were excluded from the study, either because they were 
performed when the children were ill, or during the first 48 hours after delivery.  Testing 
thyroid function at these times yields results which are difficult to interpret, as they cannot 
be used to categorise a patient’s thyroid status.  It is known that non-thyroidal illness (and 
possibly administered drugs) can interfere with the TFT results, and may indicate 
abnormalities which are not necessarily truly reflective of thyroid dysfunction.  Different 
TFT results may be obtained once the illness has resolved.  Additionally, the newborn 
experiences a TSH surge post-delivery as part of the normal physiological processes which 
occur shortly after birth. This elevated TSH level usually returns to normal levels after the 
initial surge in healthy newborns (Brown, 2001; Rossi, Caplin & Alter, 2004).  The fact 
that TFTs were performed shows that the awareness of thyroid dysfunction in DS exists, 
but that the implications of testing at the correct times are not fully understood.   Increased 
awareness amongst health professionals is needed to ensure that the TFT testing takes 
place at the appropriate times.  
 
4.4 TESTING STRATEGIES 
 
Of the patients who had no TFT result, 11/64 (17%) had insufficient blood submitted for 
analysis.  All TFTs are performed on venous blood, usually obtained from a peripheral 
vein.  The reason too little blood was submitted may be that phlebotomy in children with 
DS may be more difficult due to their short necks and tendency to become overweight, 
requiring an experienced phlebotomist to perform the venepuncture.   
 
There are currently no alternatives to routine venepuncture in Johannesburg. However, 
both Noble et al (2000) and Murphy et al (2008) concluded that a finger/heel prick blood 
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test was just as valid as routine venepuncture, at least in testing for hypothyroidism, which 
is the main form of thyroid dysfunction in our cohort.  This less invasive method of 
obtaining a blood sample from the children with DS may overcome the reluctance by 
parents and doctors to have the children tested.  It may also circumvent the technical 
difficulties involved in routine venepuncture, and lessen the trauma experienced by the 
child, thus promoting compliance with screening protocols.   
 
The necessary technology is available in South Africa to undertake heel prick TSH testing.  
This could be a consideration for the future of thyroid testing and monitoring of children 
with DS, as it is easily performed by minimally trained staff and would be a good option 
for testing in the peripheral hospital and primary healthcare setting. 
    
4.5 THYROID FUNCTION TEST RESULTS 
 
4.5.1 TFT DISTRIBUTION CURVES  
Both the TSH and FT4 distributions were non-normal curves (see figures 3.8, 3.9, 3.10 and 
3.11 in Chapter 3).  As Hübner et al (2003) also reported a non-normal distribution, we 
expected the results from our cohort to behave similarly.  Van Trotsenburg et al (2006) 
noted that neonates with DS had a FT4 distribution curve which was normally distributed, 
but shifted to the left of the normal curve observed in non-DS neonates.  Perhaps this 
finding is peculiar to neonates with DS.  Unfortunately, in the present study, there were too 
few results from neonates with DS to produce a comparable distribution curve.  There were 
also no non-DS control patients for comparison. 
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4.5.2 DIFFERENCE OBSERVED BETWEEN THE HOSPITALS  
A difference between the medians of the TFTs from the three hospitals was anticipated, as 
they use different machines to analyse their thyroid function tests.   There was no 
difference between the hospitals with regards to other variables (age ranges, race 
stratification, gender stratification or chromosome results).  The analysis of variance 
confirmed a statistical difference between CHBH and the other two hospitals (p<0.05), but 
not between CMJAH and RMH (p>0.05).  Thus the difference could only be accounted for 
on the basis of the laboratory at CHBH using a different biochemical analysis.   
 
The child referred to in section 3.6 was tested at CHBH and CMJAH, a week apart.  Using 
the result from CHBH, we may have classified this child as having SCH.  However, the 
repeat test at CMJAH was within normal limits for his age.  Thus, in an attempt to make 
the interpretation of results easier, all TFT specimens from the GC clinic at CHBH were 
referred to CMJAH for analysis from 2005. 
 
The difference observed (p<0.05) between the CHBH laboratory and the other hospitals, 
with regards to all results and the group of TSH results greater than 10mIU/L, also 
highlights the possibility that there may be inter-laboratory differences when TFTs are 
analysed at other hospitals.  This confounds the difficulty of interpretation of TFT results 
when patients are tested in peripheral hospitals. 
 
4.6 COMPARISON WITH REFERENCE RANGES 
 
The Advia® Centaur TM was used to establish the TFT paediatric reference ranges (Hübner 
et al, 2003), which were adopted as the NHLS reference ranges (see Appendix B).   These 
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reference ranges were derived from a study performed on healthy German children, and are 
specific age-dependent ranges calculated using that specific machine. 
 
Manufacturers recommend that laboratories calculate their own reference ranges, based on 
their specific biochemical machine and population.  However, this is often not feasible, as 
setting up reference ranges is time-consuming and costly, and there are ethical issues 
concerning venepuncture in healthy children for no clinically-indicated reason.  Hübner et 
al (2003) found that their results differed from a previous study, conducted in the United 
States of America using a different machine for the analysis of the TFTs.  They postulated 
that the difference arose due to the different populations tested, i.e. American rather than 
European children, rather than the machine involved.  All biochemical assays should be 
standardised according to international standards.   
 
As previously noted, the three hospitals in this study have three different machines, which 
run three different biochemical assays for the analysis of TFTs.  The machine at CMJAH is 
the exact one used in the study by Hübner et al (2003).  One could argue therefore, that 
using the reference ranges from the Advia® Centaur TM would only be useful for TFTs 
analysed at CMJAH.  However, it may not be possible for each laboratory to derive their 
own reference ranges, and clinicians may have no choice but to continue using reference 
ranges, which strictly speaking, may not be the most accurate ranges for their particular 
patients or hospital. 
 
Moreover, doctors are faced with the challenge of trying to interpret results from African 
children, using reference ranges derived from a different population.   The situation is even 
more complicated when those African children also have DS.  There are no recommended 
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TFT reference ranges for children with DS; doctors the world over have had to continue 
treating their patients with DS based on local reference ranges, derived from studies on the 
general population. 
 
4.7 SPECTRUM OF THYROID DYSFUNCTION  
 
It was not possible to superimpose a distribution curve derived from the reference ranges 
onto the curve obtained from this sample, as insufficient information about the reference 
cohort was available and a different statistical analysis was used in the derivation of the 
normal range values.  However, a comparison of the individual TFT results to the reference 
range values was possible.   Tables 3.12 and 3.15 show the range of thyroid dysfunction in 
the patients from CMJAH/RMH and CHBH, respectively.  The frequencies of SCH and 
OHT were comparable to those of other international studies.  However, it was not possible 
to compare the present rates of CHT, as most of the patients in this study were not screened 
during the neonatal period.    
 
4.7.1 CONGENITAL HYPOTHYROIDISM 
Although 23.5% of newborns in this study were found to have CHT, this figure should be 
interpreted with caution.    It cannot be compared with figures quoted in international 
studies (1.1% to 6% - see table 1.5), as all their newborns with DS are tested for thyroid 
dysfunction, as part of an NBS programme.  Most of the children in this study were not.  It 
is therefore not possible to state categorically how many of the present sample of children 
with DS were born with CHT. Additionally, there is no national NBS; hence there is a 
delay not only in the diagnosis of thyroid dysfunction in children with DS, but also in the 
general population. 
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We refer to the infant seen at RMH (section 3.6.2.3) who had a deranged TFT result at the 
age of 30 days.  One can only speculate that she was probably born with abnormal thyroid 
function.  Had all children in this cohort been tested within the newborn period, a more 
accurate CHT frequency rate could have been calculated.   
 
4.7.2 SUBCLINICAL HYPOTHYROIDISM 
The most common form of thyroid dysfunction in this cohort was SCH (see section 3.6.3.5 
on page 55 for details).  This figure (25.3%) falls within the broad range of SCH noted in 
the studies summarised in table 1.5. 
 
There were 39 patients in the cohort with a TSH level greater than 10mIU/L.  However, 
only 30.8% (12/39) of these patients were reportedly on thyroxine replacement treatment. 
As mentioned in the Introduction, the UK DS guideline, amongst others, supports 
treatment for patients with subclinical hypothyroidism with TSH levels greater than 
10mIU/L (UK - Down Syndrome Medical Interest Group, 2005).  Additionally, the AACE 
and ATA recommend beginning thyroxine treatment when TSH values exceed 10 mIU/L 
in the general population (Hollowell et al., 2002; Surks et al., 2004). The consensus 
statement of the Endocrinology and Diabetes Committee of the Royal College of 
Physicians of London and the Society for Endocrinology also supports treatment at the 
threshold of TSH greater than 10mIU/L (Vanderpump, Ahlquist, Franklyn et al., 1996).   
 
The local result is largely due to non-referral and delays due to retesting.  However, 
accurate information about the treatment practices at CHBH, the Developmental Clinics 
around Johannesburg or the peripheral hospitals, was not available.  Thus more children 
with DS may be on treatment than have been documented in the present study.   
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4.7.3 OVERT HYPOTHYROIDISM 
The frequency of OHT documented in this study was 3.6%, which falls at the lower end of 
the ranges quoted in the international studies (see table 1.5).  All the patients from CMJAH 
and RMH, who had OHT with TSH levels greater than 10mIU/L were on treatment.  
However, not all with TSH values less then 10mIU/L were on treatment, due to the lack of 
referral to the Endocrine Clinic.   
 
4.7.4 HYPERTHYROIDISM 
No patients in this cohort had hyperthyroidism.  This was in contrast to the published 
literature, where figures range between two to three percent.  The patients with DS in the 
study by Cutler et al (1986) had a similar age distribution to this cohort, and two percent of 
their patients were hyperthyroid by age three (see table 1.5).  The reasons for the 
discrepancy noted in this study may be two fold.  Firstly, because congenital 
hyperthyroidism can present with normal, abnormally high or abnormally low thyroid 
hormone levels, the diagnosis remains complex (Brown, 2001; Braverman and Utiger, 
2005).  There is no dedicated screening protocol to diagnose at-risk newborns.  Mothers at 
the antenatal clinics around Johannesburg are also not routinely screened for thyroid 
hormone abnormalities (Dr J. Jeebodh - personal communication).  Secondly, few tests 
were performed in later childhood, while it is well known that thyroid dysfunction in DS 
increases with age (Pueschel and Pezullo, 1985; Pueschel et al., 1991; Karlsson et al., 
1999).  The mean age of diagnosis of hyperthyroidism in the study by Goday-Arno et al 
(2009) was 16.8 years.  Fewer TFTs performed means fewer confirmed diagnoses of 
thyroid dysfunction.     
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4.7.5 FURTHER ABNORMAL RESULTS 
Some FT4 results from the study proved challenging to interpret.  Some results (14/516; 
2.7%) showed isolated decreased FT4 in the presence of a normal TSH level.  There may 
be several explanations for these results (refer to table 1.3).  These results may be 
suggestive of central hypothyroidism.  Further investigation is needed in these patients to 
exclude intracranial pathology.  We have no evidence that these patients were ill or on any 
form of drug treatment, which may have caused similar results (Wallach, 2000).   
 
An isolated increased FT4 was found in 19/516 (3.7%) results.  This may indicate an 
inadequate central response.  In the normal situation, an increased FT4 would form a 
negative feedback loop which would result in a decrease in the TSH level.  If there is an 
inadequate response from the hypothalamic-pituitary-thyroid axis, the TSH will not 
respond, and would remain higher than expected, though still within the normal range.  
Several patients with DS at the CMJAH Endocrine Clinic have shown similar results (Dr D 
Segal - personal communication).  Further endocrine investigation is indicated in these 
patients.    
 
Further interesting results included 12/516 results (2.3%), in which both TSH and FT4 
were elevated.  This finding could be explained by any of the reasons given in table 1.3.  
There is no evidence that children with DS are at any greater risk than the general 
population to develop any of the mentioned underlying causes of elevated TSH and FT4.  
There is also no documentation that any of these patients were on thyroid hormone 
replacement therapy at the time of these tests.  Further endocrine investigation of these 
patients is indicated. 
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4.7.6 CAUSE OF THYROID DYSFUNCTION 
As detailed in the Introduction, many theories exist as to the cause of thyroid dysfunction 
in the DS population.  Blood tests for anti-thyroid antibodies and serum zinc levels are 
available locally, although the genetic testing for thyroid receptors and other genes are not.   
No further investigation into the cause of the thyroid dysfunction was performed on this 
cohort; thus the main cause of their thyroid dysfunction remains unknown.  Results 
discussed in section 4.7.5 show that there may be inadequate thyroid and central responses 
to increased FT4 and TSH, respectively.  However, once again, the underlying mechanisms 
remain elusive.  This situation mirrors the trend in the DS literature, where the causes of 
thyroid dysfunction are still being hypothesised.  
 
4.7.7 CONSEQUENCES OF SUBCLINICAL THYROID DYSFUNCTION 
None of the patients were tested for the reported SCH-related side-effects.  Thus, there is 
no available data to document whether the patients with SCH have lipid dysfunction.  
Additionally, since the prevalence of cardiac dysfunction is higher in children with DS due 
to their chromosome abnormality, it would be difficult to document how much of the 
dysfunction could be attributed to the SCH.  The same is true for the neurobehavioural 
difficulties experienced by children with SCH, which may be viewed as part of the DS 
phenotype.   
 
 
4.8 EFFECT OF DEMOGRAPHIC VARIABLES ON THE TSH 
VALUES 
 
The analysis in 3.7 showed that older children were less likely to have TSH values greater 
than 10mIU/L.  This is not in keeping with what is known about thyroid function in DS, 
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where the trend is the exact opposite.  In fact, TSH seems to increase with age in 
individuals with DS (Pueschel and Pezullo, 1985; Pueschel et al., 1991; Karlsson et al., 
1999).  However, this finding should be interpreted with caution, as there were very few 
results for children in the older age categories.  Once more, this re-emphasises the need for 
testing in older children.  The analysis also showed no influence of other demographic 
variables, including gender, on the TSH levels.  As very few patients belonged to other 
race groups or DS-subtype groups, larger samples will be needed for a more accurate 
analysis.    
 
4.9 PATIENT FOLLOW-UP 
 
Every effort is made by the doctors and genetic counsellors in the GC clinics to ensure that 
annual thyroid function testing is performed on all patients with DS.  Few data are 
available as to whether these tests are being performed.  In this study, a total of twelve 
(3.7%) of the 327 patients who had a TFT done, had regular annual testing.  The majority 
of these tests were still being performed within the tertiary hospital setting, showing that 
the TFT surveillance has not been devolved to the secondary and primary care levels.   
A large proportion of the patients who were included in the present study were lost to 
follow-up (80%; 155/194), despite the fact that the GC clinic file documents at least two 
telephone numbers and a street and postal address for every patient.  This statistic is 
disturbing.  A more effective means of maintaining contact with the patients needs to be 
found.  It is hoped that the patients have received the GC letters, and are accessing medical 
care and surveillance wherever they are.   
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Furthermore, a more practical and streamlined process needs to be implemented in order to 
enable better patient compliance with the thyroid surveillance protocol.  This may include 
establishing a specialised DS Clinic, which would run once a month and offer endocrine, 
genetic, cardiac, physiotherapy, occupational and speech therapy on the same day.  
Currently, patients need to make several trips a month to the tertiary hospital to access 
these services, which is inconvenient and costly.  With a dedicated DS clinic, patients 
would only need to travel to the tertiary hospital once a year for a thyroid and cardiac 
check-up, if the latter was also necessary.  The therapists could make sure that the parents 
are able to continue effective therapy at home, while regular therapies could continue at 
their local hospitals/clinics.  More frequent visits to the tertiary centre would only be 
necessary for more regular surveillance in certain patients.   This approach may enhance 
not only the compliance with the medical surveillance, but will provide a platform for 
parents of children with DS to meet one another and to discuss issues surrounding DS.  
 
4.10 REFERRAL INFORMATION 
 
There were many patients with abnormal TFT results, who were never referred to the 
Endocrine Clinics.  Overall, more than a third of patients (36.6%) with a TSH level greater 
than 10mIU/L were not referred to the endocrinologist immediately as far as could be 
ascertained.  The figure is even higher (53,9%) for those patients who had a TSH level 
between the upper limit of the reference ranges and 10mIU/L.  Although the problem of 
referral seems less pronounced at the CMJAH and RMH, the fact remains that there are 
still many patients who have remained without adequate endocrine assessment and 
treatment at all the tertiary hospitals.  This can partly be explained by the lack of a 
standardised guideline, outlining the need for active thyroid surveillance of children with 
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DS.  Testing, as the first step in the surveillance protocol, cannot benefit the patient if it is 
not followed by appropriate referral practices.   
  
Delaying immediate referral of the two hypothyroid neonates mentioned in 3.8.1, meant 
that the opportunity to treat their congenital hypothyroidism was missed.  Both patients are 
currently on treatment, which was instituted later in infancy, but their cases highlight the 
need for a lower threshold for referral and treatment in neonates with DS.  Another seven 
neonates were found to be hypothyroid at CHBH; no treatment information about them 
was available during the course of this study.   
 
Whether the patients were tested by the geneticists or other specialists did not seem to 
make a difference to the referral practices.  Although the preferences of the Endocrine 
Clinics have been documented here, this information is not widely available to the GC 
Clinic staff or other healthcare professionals caring for children with DS.  It is hoped that 
wider publication of these preferences will prompt doctors to have a lower threshold for 
referral to the specialist endocrinologist.         
 
4.11 TREATMENT PRACTICES 
 
The controversy surrounding SCH seemed to extend to the present study cohort as well.  
While the paediatric endocrinologists believe that the SCH is a true reflection of the 
patients’ thyroid status, they differ as to the appropriate management thereof.   
 
These two different approaches from the tertiary Endocrine Clinics at CMJAH and RMH 
(as previously detailed in the Introduction) could each be justified.  Presently, one could 
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not judge which approach has a better outcome for the children with DS.  One way to solve 
the controversy would be to design a study to compare the long-term developmental 
outcomes of the two groups of children.   
 
4.12 SUMMARY OF THE MAIN PROBLEMS IDENTIFIED IN THIS 
STUDY 
 
The number of patients not referred after an abnormal TFT result is alarming.  Often, the 
TFT was repeated, but no further action was taken as regards referral and treatment.  The 
problem is of greatest concern, when the thyroid dysfunction is detected in the sensitive 
neonatal period.   
Many patients with abnormal results, and some of those, who had never had a TFT, were 
lost to follow-up: of these 194 patients, only 22 (11.3%) came for a repeat TFT.  
 
Despite all efforts to ensure that annual TFTs are being performed on children with DS 
following discharge from the GC clinics, very few have regular thyroid function testing.  
These are generally not performed outside of the tertiary hospital setting.   
 
Due to the statistical difference observed between the laboratory at CHBH and the other 
two hospitals, questions have arisen as to the manner in which TFT results are interpreted 
at the different hospitals.  This discrepancy needs to be addressed, in order for difficulties 
with interpretation of results to be resolved. 
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4.13 CONCLUSION 
 
This study highlighted several important issues regarding the diagnosis, referral and 
management of children with DS as regards thyroid function.   
 
Given the resource constraints placed on the healthcare system by the burden of other 
diseases like HIV and TB, an overall thyroid testing rate of 84% in this cohort is 
remarkable.  However, these tests are still only being requested by specialists and sub-
specialists.  Importantly, although most of the children in the study were tested, there 
seemed to be a less structured approach to referral of those children found to have 
abnormal TFT results.  This has left a large proportion of children who needed referral and 
treatment, without the necessary management and care.  It is hoped that the broader 
knowledge of the Endocrine Clinic preferences will allow for more timeous referrals in 
future.   
 
More research is needed to establish whether it is feasible in our setting to change the TFT 
testing modality to that of a finger/heel prick.  This may ensure better parental and patient 
compliance with thyroid surveillance, especially outside the tertiary hospital setting.   
 
The establishment of a DS Specialist Clinic would also allow for the multidisciplinary care 
of children with DS and facilitate suitable health surveillance in this population of children, 
at least for the short-term.  An ideal long-term solution would include devolving the 
thyroid surveillance of children with DS to the secondary or primary healthcare settings.  
This would necessitate national guidelines for the health supervision of children with DS to 
be adopted by all hospitals.  However, difficulties with staff numbers, available qualified 
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phlebotomists, biochemical analyses and reference ranges needs to be borne in mind, along 
with the need for education of the healthcare providers at such institutions.   
 
Difficulties with interpretation of TFT results in the Gauteng population of children with 
DS were discussed.   Special mention was made of the fact that the TFT paediatric 
reference ranges were derived on a particular machine using European children; thus 
interpretation of TFTs analysed on different machines and on South African children in 
general, and South African children with DS in particular, may prove challenging.  
Additionally, there is an urgent need for the discrepancy between the laboratories at the 
various tertiary hospitals in Johannesburg to be resolved. 
 
Increased communication and inter-disciplinary discussion among health professionals 
caring for children with DS will improve the overall care provided and ensure that all 
parties are aware of the necessary surveillance and other medical and social issues faced by 
children with DS. 
 
Finally, there is a need for a uniform, standard protocol, outlining the health supervision 
needs of children with DS, which includes thyroid function testing, referral and treatment 
guidelines.  Thyroid dysfunction can be easily and cost-effectively treated.  There is thus 
no justification for leaving thyroid dysfunction untreated in this vulnerable population of 
children, especially as it affects their cognitive abilities and developmental potential.   
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5. CONCLUSION 
5.1 CHALLENGES 
 
Left untreated, hypothyroidism causes irreversible mental and physical handicaps.  It is 
therefore desirable to detect hypothyroidism as early as possible in any individual, but even 
more so in children who already have a predisposition to learning disabilities and growth 
impairment.   
 
Optimising the care for children with DS should be prioritised.  It is vital that a 
standardised, national surveillance protocol be established to specifically address the health 
needs of children with DS in South Africa, while taking into account the country’s limited 
resources.  The guideline would need to include, among others, protocols for thyroid 
surveillance, which would standardise the monitoring of thyroid function across the 
country.   Ideally, this would include TFT testing for all newborns with DS, regular thyroid 
surveillance of all children with DS, active and appropriate referral for monitoring and 
treatment, less invasive testing techniques, and the facilities to have these tests as close to 
their homes as possible, preferably in the primary or secondary hospital systems. 
 
However, the immediate implementation of such a guideline is hampered by several issues.  
The first of these issues is the discrepancy between the laboratories noted in this study.  
Urgent studies are needed to delineate the exact causes of the differences.  Should the 
laboratories not be able to reconcile the differences and standardise the TFT analyses, 
alternatives like the heel prick tests should be urgently optimised.  The supervision 
guidelines would not be feasible in the absence of a standardised test, which delivers easily 
and reliably interpretable results.  Whether establishing DS-specific TFT reference ranges 
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would prove beneficial in the South African health care setting, also requires further 
consideration. 
 
Secondly, the absence of a NBS policy in South Africa means that children with DS who 
have CHT are not being diagnosed during the neonatal period, which is the ideal time to 
institute treatment.   Instituting a national NBS to test for thyroid dysfunction at birth, will 
not only benefit newborns with DS, but the general population of neonates as well.   
 
Furthermore, little is currently known about the referral and treatment and surveillance 
practices at peripheral hospitals. It was also noted that although children with DS are given 
a letter upon discharge from the GC clinics requesting annual TFTs from their local 
hospital, there is no record that these tests are being performed.  Enhanced communication 
is needed amongst the professionals who care for children with DS, so that the goal of 
standardizing their care can be achieved.   
 
While most children with DS are being actively tested at least once for thyroid dysfunction, 
the next steps in the management chain are conspicuously lacking.  Children are not being 
referred timeously and are therefore not receiving treatment.  Increased education of health 
care professionals and parents is needed to ensure that not only regular surveillance, but 
appropriate referral and treatment, takes place to guarantee the best care for children with 
DS.   
 
Without the above-mentioned prerequisites, a national DS surveillance guideline would be 
of little practical value.  It is hoped that the results of this study will increase awareness of 
the current challenges, and form the basis for discussion around the management and care 
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of children with DS in South Africa, finally leading to more structured protocols regarding 
health screening and treatment of complications associated with DS.  
 
5.2 FUTURE RESEARCH 
 
This study highlighted several challenges faced by doctors caring for children with DS.  
These challenges should be viewed as opportunities for future research.  The first urgent 
study which needs to be conducted should focus on resolving the discrepancies between 
the hospital laboratories’ TFT assays, so that TFT result interpretation can be standardised.   
The results from such a study would provide the necessary impetus to investigate whether 
DS-specific TFT reference ranges should be proposed. 
 
Further studies in the field of thyroid function in DS could focus on 
 investigating the cause of the thyroid dysfunction in this population of children 
with DS,  
 exploring the viability of alternative testing techniques, 
 investigating whether SCH has other adverse effects on children with DS,  
 examining whether thyroxine treatment in the absence of overt hypothyroidism 
affords children with DS a developmental or growth advantage,  
 reproducing this study in other areas/hospitals/provinces to identify if similar 
challenges are faced in other parts of South Africa 
 
Results from these studies would increase our knowledge of thyroid dysfunction in the 
South African population of children with DS, and contribute positively towards improving 
their care.  
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Appendix A: Summary of the country-specific guidelines 
for the thyroid surveillance of children with DS  
 
COUNTRY 0-1 MONTH 1-12 MONTHS 1-5 YEARS >5 YEARS 
UNITED 
STATES OF 
AMERICA 
(American 
Academy of 
Pediatrics – 
Bull, 2011) 
Routine NBS1 TSH at 6 
months and 1 
year 
TSH annually TSH annually 
UNITED 
KINGDOM 
(Down 
Syndrome 
Medical 
Interest 
Group –
2005) 
Routine NBS1 a. Full TFT with 
thyroid antibody 
tests at  1 year 
and 2 yearly 
thereafter 
or 
b. TSH finger 
prick annually 2 
a. Full TFT with 
thyroid antibody 
2 yearly 
OR 
b. TSH finger 
prick annually 2 
a. Full TFT with 
thyroid antibody 
tests 2 yearly 
OR 
b. TSH finger 
prick annually 2 
CANADA 
(Down 
Syndrome 
Research 
Foundation-
2006) 
Routine NBS1 TSH and FT4 at 
6 months and 1 
year 
TSH and FT4 
annually 
TSH and FT4 
annually 
IRELAND 
(Down 
Syndrome 
Association-
2006) 
  
Routine NBS1 Nil a. Full TFT 
OR 
b. TSH finger 
prick (if 
available) 
annually 
a. Full TFT 
OR 
b. TSH finger 
prick (if 
available) 
annually 
EUROPE  
(European 
Down 
Syndrome 
Association-
2002) 
 
Routine NBS1 TFT3 at 6 
months and 1 
year 
TFT3 annually TFT3 annually 
1NBS (Newborn screening programme): may differ from country to country, and within the USA from state 
to state; generally includes TSH and FT4 
2 Finger prick must be followed by venous TSH, FT4 and thyroid antibodies if initial TSH is raised  
3 Different European countries have different practices: some may do a full TFT, other may only test the TSH 
levels 
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Appendix B: NHLS Paediatric TFT reference ranges  
 
AGE TSH  
mlU/L 
FT4  
pmol/L 
FT3  
pmol/L 
1- 3 days 0.13-9.23 10.8-26.8 2.3-8.1 
4 - 30 days 0.16-8.48 10.9-25.5 2.4-7.9 
31 - 60 days 0.19-7.78 11.0-24.3 2.5-7.8 
2 months-1 year 0.3-5.88 11.4-20.9 2.7-7.3 
1 - 5 years 0.42-4.79 11.4-19.0 3.1-6.9 
6 -10 years 0.48-4.67 11.0-18.8 3.3-6.8 
11 -14 years 0.53-4.58 10.8-18.7 3.5-6.7 
15 - 18 years 0.56-4.53 10.7-18.7 3.6-6.7 
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Appendix C: Data Collection Sheet  
CODE HOSP GENDER RACE DATE 
OF 
BIRTH 
AGE DATE 
OF 
TEST 
TEST  
REQ 
CHROM. 
RES 
TSH FT4 REF 
Y/N 
ON Rx 
AT 
ENDO 
Y/N 
             
             
             
             
             
             
             
             
             
             
             
             
             
CODE: anonymous patient code 
HOSP: hospital 
TEST REQ: test requester 
CHROM RES: chromosome result 
TSH: thyroid stimulating hormone 
FT4: free thyroxine 
Ref Y/N: referred to Endocrine Clinic, yes or no 
On Rx at EndoY/N: on treatment at Endocrine Clinic, yes or no 
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Appendix D: Ethics Approval Certificate  
 
